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Nanomedicines have long been expected to significantly enhance cancer treatment. However, 
their clinical translation is still very limited despite of the world’s great efforts during the last 2 
decades. One of the reasons is that the transport barriers within tumors restrict their penetration 
into tumors, with most nanomedicines remaining among the top submicrometer to several 
micrometers scale. Therefore, there is an extensive interest in the field to understand the tumor 
microenvironment and develop techniques to boost the penetration of nanomedicines in tumors. 
This review emphasizes the need of smart nanotechnology to fit the changing requirements of 
nanomedicines for effective drug delivery, particularly the technologies for deep penetration of 
nanomedicines in tumor tissues, and explores their mechanisms in order to achieve multistage 




disadvantages of current approaches to facilitate the deep penetration of nanomedicines are 
discussed and possible future avenues for smart nanotechnology are identified. 
1. Introduction  
Cancer is the second-leading cause of mortality in the world; 1 in 6 deaths worldwide is a result 
of cancer which equates to 9.6 million deaths per year.[1] Apart from surgery, chemotherapy is 
extremely important for patients who are unsuitable for surgery and for tumors that cannot be 
completely removed, while the non-targeted nature of chemotherapeutic drugs often causes 
systemic toxicity due to the inability to differentiate healthy cells from tumor cells. Gratefully, 
due to the fast development of nanotechnology, i.e. targeted delivery fulfilled by 
nanomedicines, the efficacy of cancer chemotherapeutics is expected to be improved. 
Nanoparticles (NPs) are defined as those measured in the nanoscale between 1 – 1000 nm, 
which have the flexibility of surface modification.[2-3] Approved anti-cancer drugs can be 
loaded onto or into NPs, as they are often referred to as ‘nanocarriers’. Commonly, nanocarriers 
are fabricated into 10 to 250 nm and could largely increase their accumulation on the tumor site 
via various targeting mechanisms, improved drug stability, and increased blood circulation half-
life.[4-6] These advantages can potentially relieve clinical side effects caused by traditional small 
molecule chemotherapeutic drugs including high damage to health tissues and short blood 
circulation half-life.[7-8]  
However, the therapeutic efficacy of numerous nanomedicines in the clinical setting is 
still quite limited despite the fact that nanomedicines are able to more efficiently transport to 
tumor regions. This is most attributed to the ineffective intratumoral penetration of the 
nanomedicines since it is not an easy task to cross several transport barriers within tumors and 
then work on the tumor cell parenchyma. Tumor cells are located in the deep area of tumor 
tissue which is protected by a dense tumor extracellular matrix (ECM), elevated interstitial fluid 




restrict the transport of nanomedicines to the tumor cells through diffusion or convection and 
they may cause drugs to be extravasated back into the blood stream.  Typically, the penetration 
depth of most targeted nanomedicines is only on the submicrometer to several micrometers 
scale (typically 3–5 cell diameters).[16] For example, Doxil® is a commercial passively targeted 
PEGylated liposomal nanomedicine, its penetration depth in mice tumor xenografts is limited 
to 18.8 μm. With prolonging time, the drug could diffuse back toward the vascular wall.[17-18] 
Thus, it is hard to desire that nanomedicines would kill all tumor cells and cure cancer with the 
current technique. Tumor is more likely to return after treatment. Consequently, the 
improvement of intratumoral penetration of nanomedicines, allowing them to perform their 
maximum anti-cancer efficiency, could be one of the most critical and tough tasks in current 
chemotherapeutic research.  
Prior strategies for achieving deep penetration depth can be divided into four main 
categories. The first is to tune the physico-chemical properties of nanomedicines. There is a 
wave of works demonstrating that NPs with small size, non-round shape and positive surface 
charge are associated with better tumor penetration. However, these optimal characteristics of 
nanomedicines for penetration compromised their tumor delivery efficiency. The reasons are 
that small NPs under 5 nm could be easily cleared in blood circulation and positively charged 
NPs will interact with the negatively charged biological system.[19-20] In other words, one-size 
or one-charge NP drug transport is hardly fitting the whole in vivo journey. To tackle this, many 
studies about dynamic regulation of NPs’ physico-chemical properties and intratumoral drug 
release have been reported using tumoral internal triggers (e.g., lower pH than blood, high 
concentration of matrix metalloproteinases, and redox) or external triggers (e.g., light, 
temperature, and ultrasounds).[21-22] As a result, the small or positive charged nanomedicines 
are only exposed to the tumor regions for improved penetration ability and have no influence 
to circulation and targeting efficiency. The second type of methods is to modulate the tumor 




hyperthermia), such as degrading dense ECM to reduce penetration hindrances, and 
normalizing abnormal vasculature to lower the IFP and to increase vascular permeability. The 
third class of strategies is to use magnetic force to drive deep penetration of nanomedicines into 
humoral hypoxic and avascular zones. The magnetic drug targeting method was proposed as 
far back as 1978,[23] but the works that examined magnetic drug targeting to improve tumor 
penetration were only reported in the past decade and this field is still at infancy. The fourth 
type of strategies is the recently developed biological approaches. 
This review systematically describes the barriers to tumor penetration and subsequently 
evaluates the effects of smart nanotechnologies to reach deep penetration depths within tumors 
in order to achieve efficient cancer treatment. Then the advantages and disadvantages of each 
approach is discussed, followed by our insights into the key issues of these technologies and 
the future development for clinical applications. The structure and contents of the review are 
summarized in Figure 1. 
2. Challenges and requirements for deep penetration of NPs 
Nanodrugs are transported to their target tumor cells in three sequential steps: vascular 
transport, trans-vascular transport and interstitial transport (Figure 2). The first of these involves 
the flow of NPs to tumor regions via blood vessels. Once this has been achieved, they must then 
pass through the vessel wall. Finally, the NPs must penetrate through the interstitial space 
between tissues in order to reach target tumor cells.[24] To ensure the final delivery of nanodrugs 
to deep tumor cells, different challenges and requirements for each stages in transport of NPs 
should be recognized and addressed. 
2.1 Barriers outside the tumor 
Before targeting tumor sites, NPs undergo many hurdles. First, all NPs have a half-life 
which governs their biodistribution and how long they circulate. The rapid clearance of NPs 




system (RES).[25-28] The RES system, found in the liver and the spleen, is important for normal 
function of the body, but the main culprit of NP clearance. The surface charge plays a huge role 
in determining the fate of the NPs with respect to the RES system. Large zeta potentials, positive 
or negative, causes more RES/NP interactions and therefore more clearance.[24] Another 
undesirable clearance is kidney filtration, while it can be reduced by careful consideration of 
particle size. The effective pore size of the glomerular wall is 8 nm; therefore, particles larger 
than this are less likely to pass through than smaller particles.[19] Second, NPs will come into 
contact with normal cells, and there is a risk of toxicity if the NPs are non-targeting to tumor 
tissue. Thus, NPs must show stability in the conditions within the blood stream. Blood vessels 
have a pH of approximately 7.4 and a negatively-charged luminal surface.[29] Surface 
modifications must stay attached under this condition, or the NPs would disintegrate and release 
cytotoxic drugs to the rest of the body. For sufficient permeability, a longer blood circulation 
is recommended. As a result, the requirements for NPs at these stages of transport are pH stable 
and neutrally or negatively charged surface modifications to alleviate the attraction of blood 
vessels, and larger size of more than 10 nm to prevent the clearance from blood circulation.[30]  
After blood circulation, the next stage is to preferentially transport to tumor sites. For 
this, two mechanisms have been proposed: passive targeting and active targeting. In passive (or 
physical) targeting, nanocarriers – a nanoscale transporter of drugs – can access tumors via the 
surrounding leaky vasculature (pore size on tumoral microvessels ranges from 100 to 1200 nm) 
due to the enhanced permeability and retention (EPR) effect (Figure 2).[31] However, the 
enhanced permeability of leaky tumor vasculature allows macromolecules to transport into the 
tumor interstitial space but is unable to facilitate permeation. Additionally, this model has now 
been seriously challenged as the EPR effect is not observed in clinical settings.[32] Danhier 
proposed that the EPR effect only works in rodents rather than humans based on thousands of 
research papers.[33] While another opinion is that the EPR effect may be existing for some 




Based on the knowledge of blood circulation and tumor targeting of anticancer drugs, 
various types of nanomedicines have been developed. The first-generation nanomedicines were 
launched about 30 years ago and some of them have been commercialized such as 
Doxil®/Caelyx®  and Myocet® (PEGylated liposomal doxorubicin), and Abraxane®  
(nanoparticle albumin-binding paclitaxel).[35-38] Subsequently, the second-generation 
nanomedicines were developed with active targeting ligands on the surface to specifically bind 
to the receptors of targeted sites. Such receptors are overexpressed by cancerous tumor cells or 
tumor vasculature in contrast to normal, healthy cells. Moieties like antibodies, antibody 
fragments, aptamers, peptides and folic acid can all act as targeting ligands.[39-42] Many of this 
generation of nanomedicines are in preclinical or clinical trial status.[43-44] 
2.2 Barriers inside the tumor 
Once across the vascular endothelial cells, the restricted deep penetration of NPs in tumors 
poses a great challenge in the fight against cancer. Despite the large number of successful 
preclinical studies, many NPs have proven inefficient in the clinical environment due to their 
inability to penetrate deep within tumors – this is a result of the tumor microenvironment and 
the physico-chemical properties of the NPs themselves.[45-46] Figure 2 illustrates the main 
barriers to deep penetration which must be rationally considered when designing and 
engineering NPs in order to establish an efficient cancer treatment.  
2.2.1 Heterogeneous vascular network 
In comparison to normal vessels, tumor vessels are highly irregular and chaotic in structure.[47] 
The tumor vasculature network is dynamic in nature and varies from tumor to tumor; it 
sometimes even varies within the same tumor type at different stages of development. 
Consequently, the combination of these factors results in unequal permeability which, 




2.2.2 Elevated interstitial fluid pressure (IFP) 
IFP is a type of stress that is applied by fluids and uniformly elevated throughout tumors. Fluid 
flows through tumors via three main processes: flow along the tumor vessels; flow through the 
interstitial space, and drainage of any excess fluid by the lymphatic vessels. Consequently, any 
irregularities in the tumor microenvironment that regard any of these three processes lead to 
elevated IFP. For example, there is a lack of functional lymphatic vessels in tumors and this 
elevates IFP. An elevated IFP has the potential to disrupt the normal convective flow and thus 
it restricts the efficacy of NP transportation to tumor sites.[48] Furthermore, due to the stresses 
placed on vessel walls by the fluid, elevated IFP has the potential to compress tumor vessels 
and thus cause the vessels to collapse which, consequently, decreases the ability of the 
nanomedicine to be transported through the tumor vasculature. Additionally, elevated IFP 
might result in loss of interstitial fluid into surrounding normal tissues. As a consequence, this 
would result in transportation of both nanomedicine and tumor, thus spreading the malignant 
cells and increasing drug resistance.[47] 
2.2.3 Stromal cells 
Stromal cells provide structure, support and anchoring for all organs inside the human body. 
They resemble ligaments in that they are connective in nature.[49] In short, they are connective 
tissue cells. The most common types of stromal cells are cancer-associated fibroblasts (CAFs) 
and tumor-associated macrophages (TAMs). Studies have found that CAFs and TAMs can 
increase the rate of proliferation and metastasis of tumor cells. More importantly, they can 
negatively impact upon the transport and drug delivery of NPs by restricting their access to 
tumor cells.[48] According to Roode et al., despite the fact that TAMs only contribute about 1% 
of all cells in tumors, the attraction of NPs to TAMs is four-fold greater than that of cancer 
cells.[50] Additionally, the attraction of NPs to CAFs is approximately seven-fold greater than 
that of cancer cells. As a result, this off-target uptake of NPs by stromal cells decreases the 




2.2.4 Dense extracellular matrix (ECM) 
Within all tissues and organs there is a non-cellular component present called the ECM. It is 
formed by the secretion of components from both stromal and cancer cells and is comprised of 
two types of macromolecules: proteoglycans and fibrous-forming proteins.[51] Such proteins 
contribute towards the structure and function of the ECM which is constantly being remodeled, 
either enzymatically or non-enzymatically. Consequently, the ECM is a highly dynamic and 
complex network that stimulates tumor metastasis. Moreover, the dense ECM also prevents 
penetration and homogeneous distribution of the targeted nanomedicine in three significant 
ways. First of all, the restricted interstitial volume coupled with the high stromal cell fraction 
contributes towards a very dense network which, consequently, diminishes the blood flow and 
limits the convection of nanomedicines. Secondly, the diffusion of nanomedicines is limited by 
the collagen thickness, fibrillar structure and mesh size of the ECM. Matrix mesh sizes are 
typically within the range of 20-40 nm and thus only very small particles can achieve deep 
penetration; therefore, as many nanomedicines exceed this range they are prevented from 
diffusing through the ECM. Thirdly and finally, the tortuosity of the tumor interstitial space 
presents an additional barrier to the penetration of all drugs as the diffusion path that 
nanomedicines must travel along, from blood vessels to tumor cells, is elongated. Conclusively, 
dense ECM networks in tumors restrict the transportation of nanomedicines in both the 
vasculature and the tumor interstitial space.[47] 
In order to overcome these four barriers and thus allow NPs to penetrate deep within 
tumors, requirements for NPs in this interstitial transport stage could be different from the 
previous two stages. From the compelling evidence generated by a number of independent 
groups, it has been confirmed that, in general, smaller and elongated NPs achieve greater tumor 
penetration than larger and spherical NPs.[48] And unlike vascular transport, positive charges 
facilitate the binding of NPs to inherently negatively-charged cell membranes and achieve deep 




3 Strategies for deep penetration 
3.1 Dynamic regulation of the physico-chemical properties of NPs 
As previously mentioned, the physico-chemical properties (e.g., size, shape, and surface 
chemistry in Figure 3) of NPs represent one factor towards determining the extent to which NPs 
can penetrate deep within tumor cells. However, an optimal physico-chemical property of a NP 
changes dramatically over time and place within the living body at different stages of 
transportation. The changing requirements of the properties of NPs at different transport stages 
have recently led to the growth of smart nanotechnology, where stimuli-responsive NPs can 
dynamically adapt in a surrounding tumor microenvironment or as a result of an external 
trigger. 
3.1.1 Size/surface charge switch upon stimuli 
Particle size plays an important role in determining how deep NPs can penetrate inside tumor 
cells. On the one hand, large particles, approximately 100 nm in size, boast advantages for high 
tumor accumulation in the leaky vasculature; on the other hand, they have poor penetration 
efficiency due to the large diffusion barrier in the tumor matrix.[48] Correspondingly, smaller 
particles are advantageous for deep penetration due to the presence of fewer diffusion barriers; 
nevertheless, they are prone to short blood circulation times and poor tumor accumulation rates 
as a result of rapid clearance.[54-56] 
Surface charge is another influential property of nanomedicines for achieving deep 
penetration. However, the results from current research studies are mixed and sometimes 
contradictory. According to Jain & Stylianopoulos, neutral NPs diffuse faster and are 
distributed more evenly within tumors than their cationic or anionic counterparts, which is due 
to the fact that charged particles can form aggregates with oppositely-charged components in 
the same matrix.[24] In contrast, in a separate study, cationic lipidic NPs of around 100 nm were 
shown to achieve increased penetration in both three-dimensional (3D) tumor spheroids and in 




suggested that the active penetration of the positively charged NPs is induced by iterative 
transcytosis.[53] However, one thing can be confirmed that negative NPs are not suitable for 
deep penetration, even in small concentration, they can form aggregates hindering penetration, 
while in an earlier study back in 2010, He et al. confirmed anionic (negatively charged) 
nanocarriers excelled in blood transport.[57] 
A trade-off between these two purposes – tumor accumulation and deep penetration – 
exists for many NPs. However, it is desirable for NPs to exhibit both of these properties in order 
to maximize their drug delivery efficacy. Resultantly, such requirements have promoted the 
development of size-switchable or surface charge-switchable NPs which are able to maintain a 
large initial particle size and negative surface charge for long circulation time, and then 
responsively switch to a small size and positive or neutral surface charge for deep penetration 
and effective tumor distribution once they have accumulated at tumor sites.[58] Within these 
dynamic alteration studies, some NPs exhibit size change, with some causing a surface charge 
reversal. But most recently there have been increasing NPs able to exhibit a dual change, in 
other words, both the size and surface charge of NPs are able to undergo concurrent alterations 
in a multistage process. The size change can be achieved by some size shrinking materials or 
intratumoral release, and dual change is commonly achieved by the latter strategy. These 
switching events can be triggered by a number of stimuli, including internal stimuli such as pH, 
hypoxia andoverexpressed enzymes, and external stimuli such as light, ultrasound and 
temperature.[45] Figure 4 displays the different types of internal and external triggers. 
pH: 
The pH in the abnormal tumor microenvironment is mildly acidic (i.e. tumor extracellular pH, 
pHe), approximately between 6.5 and 7.0, which is lower than that in normal tissues and blood 
(≈7.4).[59] The pH value can further decrease to 4.5-6.0 in the lysosome/endosome (i.e. tumor 
cell intracellular pH, pHi).[60] Such a disparity in pH values can be utilized in order to trigger 




example, Dai et al. took advantage of two pH sensitive substances 2‐propionic‐3‐methylmaleic 
anhydride (CDM) molecule and poly(2‐(diethylamino) ethyl methacrylate (PDEA) to produce 
a size/charge dual changeable micelleplex for enhanced tumor penetration.[61] The acid-
cleavable amide bond (pKa 6.8) from CDM provided the function of size shrinking at weak 
acidic tumor microenvironment pHe and then the ultra‐pH‐sensitive polymer, PDEA (pKa ≈ 
6.4) core, was quickly protonated in pHi which provided the spiraling positive charge and 
triggered the release of cargos. As a result, the size of the micelleplex reduced from 111.7 to 43 
nm, and its surface charge increased from 11 to 35 mV. When multicellular tumor spheroids 
(B16F10 cells) were incubated with micelleplex at pH 6.8 for 4 h, the fluorescence signal of 
micelleplexes in spheroids was 7-times higher than that of pH 7.4.  Wang and colleagues 
constructed ultra-pH sensitive cluster nanobombs (SCNs) by linking small platinum prodrug-
conjugated poly(amidoamine) (PAMAM) derivatives (PAMAM/Pt) particles to ultra-pH-
sensitive PEG-PAEMA so that the amphiphilic polymer containing ionisable tertiary amine 
groups could facilitate rapid pH- responses.[62] Such superstructures had an initial size of 80 nm 
following IV injection; however, after accumulation in the tumor microenvironment, smaller 
NPs of less than 10 nm were generated (Figure 5A). Such size-switchable NPs showed 
significantly improved tumor penetration and drug delivery efficacy in comparison to pH-
insensitive NPs that remained around 80 nm in size. Chen et al. designed and reported a shell-
stacked NP (SNP) which could undergo both size and surface charge transformations.[63] Such 
a transformation was brought about by cleavage of dimethylmaleic anhydride (DMA) groups 
from methoxy poly(ethylene glycol)-block-poly(l-lysine) polymer in mildly acidic tumor 
microenvironments. As a result, the NP size was reduced from about 145 to 40 nm and the 
surface charge was reversed from -7.4 to +8.2 mV, which is a remarkable change (Figure 5B). 
In vivo investigations found that SNP penetrates about 1.1 mm inside the tumor mass 
(xenografted A549 lung carcinoma), which is about fourfold deeper than that achieved by its 






Matrix metalloproteinases (MMPs) are the main ECM enzymes in collagen degradation which 
occur in numerous different types of cancers.[64-67] Therefore, a strategy to trigger size-
shrinkage of NPs can be based on the overexpression of MMPs, particularly MMP-2, in the 
tumor microenvironment. Gelatin is a substrate of MMP-2 and the enzyme degrades gelatin. 
With this principle, Wong et al. proposed a multistage system whereby gelatin NPs “shrank” in 
size from 100 to 10 nm after entering the tumor vasculature and being exposed to proteases 
such as MMP-2 due to the degradation of the cores NPs.[68] Moreover, Ruan et al. developed a 
similar construction of a kind of novel nanocarrier, G-AuNPs-DOX-PEG, which is a gelatin 
and gold composite NP loaded with DOX for enhanced tumor penetration.[69] Such a NP can be 
degraded by MMP-2 which causes the size to shrink from ~186 to ~59 nm. Thus, this type of 
NPs have been found to efficiently inhibit tumor growth in 4T1 and B16F10 tumor models in 
mice. Treating such tumor bearing mice with these NPs resulted in the lowest tumor growth 
rate. Consequently, size-shrinkable G-AuNPs-DOX-PEG are capable of exhibiting the best 
anti-tumor effect due to deep penetration of the NPs following by release of DOX. 
Hyaluronidase (HAase) is another specific enzyme which is highly expressed in tumor 
microenvironment.[11, 70-71] Similar to MMP-2, HAase can cause the degradation of hyaluronic 
acid (HA) and then trigger the size shrinking of NPs whose shells are made by HA. Hu et al. 
presented hyaluronic acid (HA) shell based size-changeable intelligent NPs, DOX-DGL/ nitric 
oxide donor-modified hyaluronic acid (IDDHN).[72] After incubation with HAase for 4h, the 
size of IDDHN NPs shrank from 264 to 29 nm and the penetration depth of IDDHN NPs in 3D 
tumor spheroids can reach 80 μm (3.5-fold higher than that of NPs without HAase incubation). 
More recent size/surface charge switchable NPs upon overexpressed enzymes are listed in 





Hypoxia is a result of a low partial pressure of oxygen found in the deeper section of the tumor 
region where there is also an absence of blood vessels.[73-76] In order to target this region, NPs 
must be able to penetrate deep into the tumor microenvironment. One approach is to create NPs 
that are attracted to hypoxic cells within tumors. Similar to regular tumor cells, hypoxic cells 
contain overexpressed markers. Hypoxic cells are specifically overexpressed in 
phosphatidylserine which can be used as a target for delivery. Despite phosphatidylserine being 
found on the external membrane of cells where apoptosis occurs, it is also found on the 
endothelial cells of tumor cells. Hypoxic conditions increase the amount of phosphatidylserine, 
making it a prime marker to target. Wojton et al. found the addition of lysosomal protein 
Saposin C (SapC) onto NPs enhanced killing efficacy for hypoxic cells and increased 
survival.[77] This study used many models of brain cancers, including glioblastoma – the most 
aggressive forms of brain tumor. Hypoxia targeted delivery could be used with NPs with size 
change, surface charge change and controllable intracellular drug release. Hypoxia condition is 
able to trigger the cleavage of several hypoxia-sensitive moieties which can perform strong 
reductive reaction, such as azobenzene (Azo), or quinone derivatives, resulting in the properties 
switch of NPs.[78-79] Thambi et al. reported the synthesis of hypoxia-responsive NPs (HR-NPs). 
Under hypoxic conditions, the NPs would undergo a surface charge increase and hydrophobic-
to-hydrophilic change via the reduction of 2- nitroimidazole to 2- aminoimidazole (Table 3).[80] 
The release of the hydrophobic drug DOX would occur in the internal hypoxic cells showing 
great targeting. 
Light: 
For photosensitive NPs, stimulation from light can be used. Light could come from ultraviolet 
(UV), visible and near infrared radiation (NIR) regions in the electromagnetic spectrum. Tong 
et al. designed spiropyran-based NPs being capable of shrinking from 103 to 49 nm upon 




conditions, the hydrophobic spiropyran was converted to an amphiphilic derivative. 
Nevertheless, the use of UV-triggered size-switchable NPs has distinctive disadvantages 
including damage to healthy tissues, and limited ability to reach tumors in deep organs. As a 
result, NIR light or far infrared laser irradiation may be preferred over UV illumination as they 
result in increased tumor penetration and greater compatibility with biological systems. You et 
al. loaded DOX onto hollow gold NPs.[82] The study used NIR laser to achieve localized 
therapy. The energy from the light excites the NPs, forcing them to release the payload. Being 
hollow allows these particles to have an increased payload, one advantage over solid 
nanocarriers. The payload of DOX could constitute up to 60% of the weight of NPs. Ovarian 
cancer types Hey and A2780, as well as breast cancer cell MDA-MB-231 were tested with the 
same outcomes. 
3.1.2 Size/surface charge switch upon multi-stimuli 
Previous discussion on recent studies has highlighted multiple ways in which NPs may respond 
to the tumor microenvironment. There have also been examples on the requirements of the 
different stages and how these have been met in recent studies. A growing topic of research has 
become multi-responsive NPs. Having multiple triggers in a process could increase NPs’ 
performance. Cun et al. produced a MMP-2 and pH dual triggered NPs, doxorubicin-conjugated 
dendrigraft-poly-L-(lysine)–EGPLGVRGK–poly(ethylene glycol)–poly(caprolactone) 
(DGL/DOX- EGPLGVRGK -PEG-PCL), which can achieve intratumoral degradation of NPs 
for twice.[83] The MMP-2 in tumor microenvironment caused the cleavage of PEG-PCL via 
EGPLGVRGK (a substrate peptide of MMP-2) hydrolysis that results in the first size shrink 
from 100 to 30 nm, and generated strong penetration of DGL/DOX in 3D in vitro model (Figure 
6). The penetration depth of NPs can reach 80 μm after incubation with MMP-2 for 1h. Then, 
the acidic tumor intracellular environment triggered the second drug release to effectively kill 
tumor cells by breaking the pH sensitive hydrazine bond between the DGL and DOX.  




concentration of GSH ranges between 2-10 mM in the tumor cells and 2-10 μM in the ECM.[84] 
This exceptionally large difference means redox triggering NPs is an effective way to induce a 
change of the nanocarrier.[85] One approach is to make use of disulfide bonds to control the 
properties and release of NPs. In ECM, disulfide bonds remain intact, while in the presence of 
reductive species, which are usually found in the tumor cells, the disulfide bonds break down. 
Using this principle, Sun et al. developed RGD-PEI-SS-PLA/PTX@MMP-2-sensitive 
nanoclusters. The MMP-2 cleavage peptide was first degraded and the disulfide bond between 
the PEI and PLA was only cleaved under intracellular high reductive condition (Figure 7).[86] 
As a result, the size of the nanocluster can be reduced from 200 to 30 nm in tumor environment 
and the redox-responsive property synergistically accelerate intracellular drug release to 
achieve favorable antitumor activity (Table 4). Addition of disulfide bonds can be implemented 
on many forms of nanocarrier including mesoporous silica NPs (MSNs), carbon nanotubes and 
PEGylation micelles which are just a few examples.[87-89] 
Additionally, several studies were reported to engineer stimuli-responsive NPs using 
both internal and external triggers. Zhou et al. designed a MMP-2, light and temperature multi-
responsive nano liposome.[90] The liposome is a temperature sensitive material containing 
MMP-2 cleavable PEG corona. An NIR laser sensitive photosensitizer, pheophorbide a (PPa), 
can produce mild-hyperthermia under NIR laser irradiation to trigger drug release. Through 
this, multiple functions like stable blood circulation, size shrinking and intracellular drug 
release were achieved in one system. The results showed that the PPa–GPLGLAG–PEG 
achieved 1.9-fold deeper penetration in 4T1 tumor spheroids compared with PPa-PEG (without 
MMP-2 sheddable ligands). Jiao et al. simultaneously used temperature and redox to trigger the 
properties change of MSNs.[91] The particles only exhibited drug release when the temperature 
was higher than 37 °C, suggesting that this technology effectively decreases risk of premature 
drug unloading as it would only occur under external stimuli. When the particles were in tumor 




cleavage of the disulfide bonds to release payload. Table 4 summarized recent examples of 
combinations of multiple stimulus to trigger size/surface charge along with their transition 
mechanism. 
3.1.3 Shape switch  
Except size change, the influence of NPs with different shapes on their penetration ability in 
tumor tissues has also been experimentally and theoretically studied. Most results confirmed 
the fact that rod-shaped NPs (including nanotubes and nanoworms) are preferable for tumor 
trans-vascular and interstitial penetration, while spherical and quasi-hemispherical NPs are 
good for subsequent uptake by cancer cells.[92-95] Therefore, it can be similarly imagined that 
shape switchable NPs will be advantaged for cancer treatment. However, this is rarely reported, 
possibly due to the difficult control.  
Recently, Wang et al. reported a shape-changing micelle called HEKM which contained 
a MMP-2 responsive linker.[96] The shape transformation was triggered by the overexpression 
of MMP-2 in the tumor microenvironment. During blood circulation, the HEKMs were self-
assembled as nanorods (diameter of 20 nm and length of 50-300 nm) for increased tumor 
targeting with the aid of a recognition element consisting of EGFR-HER2 targeting peptide and 
mitochondrial apoptotic peptide and enhanced internalization. Once HEKMs penetrated into 
the tumor matrix, their MMP-2 responsive linkers were sheared, resulting in shape 
transformation from rod to sphere (diameter of around 35 nm) for better uptake by cancer cells 
(Figure 8A-E). In additional to this strategy, pH sensitive cross-linking single polymer chains 
can provide another great opportunity to fabricate shape switchable NPs since they can mimic 
the reversible folding procedure of proteins and self-assemble into well-defined shape. Song et 
al. reported a single-chain tadpole polymer PDEA-b-P(OEGMA-co-PDS) (named SCTP), 
which performed controlled shape switch triggered by pH change.[97] At pH 7.4, SCTP was 
deprotonated to hydrophobic and self-aggregate into large (68.7 ± 2.8 nm) spheroid-like multi-




(9.6 ± 0.3 nm) rod-like SCTP for deep penetration in tumor (Figure 8F).  
Inspired by the self-regulation of conformation in response to biological signals of 
proteins, Ohta et al. designed a shape-shifting nanostructures using three different sizes of gold 
NPs as cores whose surfaces were decorated with folic acid as the targeting molecule and linked 
with DNA sequences to control shape switch.[98] Upon addition of an attaching strand (A1) and 
a detaching strand (L1comp), the assembled nanostructure will change to another shape 
(morphology 2) by reconfiguring the DNA assembly (Figure 9A, B). The targeting ligands folic 
acid were hidden in the morphology 1 and exposed on the surface in the morphology 2 (Figure 
9C). The results showed that even without targeting molecules (folic acid), the cellular uptake 
(U87-MG cells) of morphology 2 was 1.5 times that of morphology 1. This strategy provides a 
new opportunity to develop future dynamic NPs which can be stable in blood travel and then 
transform into desirable shapes to overcome various biological barriers at disease sites. 
3.1.4 Surface biochemistry 
Apart from redesigning NPs size, shape and surface charge to optimize their transport and 
penetration kinetics, surface biochemistry as well as hydrophobicity can lead to the same effect. 
One of the advantages of NPs is the flexibility of surface modifications for properties control.[99] 
One way to improve the efficacy of drug delivery is to coat the surface with polyethylene glycol 
(PEG) – a process known as PEGylation. PEG coatings boast advantages for improved blood 
circulation, as they shield the surface from aggregation, opsonization, and phagocytosis. Hanes 
and colleagues discovered that large NPs coated in PEG are able to penetrate tumors that were 
previously considered impenetrable by uncoated particles if, and only if, they are densely 
coated.[100] Such densely coated particles can also rapidly diffuse within the tumor 
microenvironment and distribute evenly throughout the tumor – the effect of which is illustrated 
in Figure 10. Surface PEGylation of NPs minimizes the interactions between particles 
themselves and the tumor ECM due to the hydrophilic and uncharged nature of PEG, thus 




The efficacy of NP drug delivery can be enhanced by decorating the surface of NPs with 
active targeting moieties. Chan et al. discovered that actively targeted NPs, within a 60 nm 
diameter range, accumulate 5 times faster and approximately 2-fold higher than their passive 
(non-targeted) counterparts; however, their penetration capabilities are significantly 
reduced.[102] This suggests that the tumor delivery efficiency and the subsequent tissue 
penetration can be conflicting. To achieve both efficient tumor accumulation and deep 
penetration, Ruoslahti discovered the advantageous effects of using a tumor-homing peptide, 
iRGD (sequence CRGDKGPDC).[103] The iRGD peptide follows a multi-step tumor targeting 
mechanism, and it can bind αvβ3/5 integrin and neuropilin-1 overexpressed on the cancer 
cellular membrane, which results in sufficiently deep tumor penetration; this is far greater than 
that achieved by conventional RGD peptides and their counterparts as they are only capable of 
transporting their drug payloads to the periphery of tumor vessels. 
Moreover, cell-penetrating peptides (CPPs)  and tumor-penetrating ligands have been 
widely used to facilitate the intratumoral penetration of NPs.[104] Hu et al. reported r9-S-S-
DOPE (CN) nanovehicle based on the r9 CPPs (Sequence: rrrrrrrrrc-SH) which exhibited great 
penetration capacity to primary tumor mass and effective anti-lymph metastasis outcome in 
mice test.[105] However, for CPPs, non-specific interactions would be unavoidable and thus 
largely affect drug delivery efficacy in in vivo studies. Therefore, to overcome this problem, a 
“ligand presentation” strategy was developed, whereby the targeting ligands were shielded, thus 
preventing undesirable interactions from occurring. The targeting ligands can then be exposed 
in response to specific internal or external stimuli, such as those mentioned above in Section 
3.1.1. For example, targeting ligands tend to be shielded by acidic detachable chemical groups 
(such as DMA connected molecules) to mask their cell penetrating function, or shown in the 
Figure 9, the “targeting ON/OFF” strategy.[98] Furthermore, more recent studies used tumor-
penetrating peptides rather than CPPs, due to their targeting ability to tumor.[106] Kwon et al. 




Unlike CPPs, LyP-1 shows specific interaction with tumor by binding its cognate receptor 
(p32), which increased the tumoral accumulation by 20% and reduced the accumulation in 
organs, compared with non-LyP-1 NPs. Several recent and novel tumor-penetrating substances 
are summarized in Table 5. 
3.2 Modulation of tumor microenvironment 
3.2.1 Degradation of ECM 
The tumor ECM is dense and comprised of collagen, fibronectin, hyaluronic acid, 
proteoglycans and stromal fibroblasts which act as barriers to deep penetration of NPs within 
tumor masses. As a result, degradation of the ECM can be considered a feasible approach to 
enhance tumor penetration of NPs.[58] 
According to Zhang et al., losartan can be injected prior to NP drug delivery treatment 
in order to decrease the level of collagen I in tumors and thus facilitate deep penetration – the 
mechanism of which is illustrated in Figure 11.[108] Losartan pre-treatment of 4T1-bearing mice 
at 40mg/kg preceding IV injection of ~100 nm PEGylated liposomes resulted in a greater tumor 
distribution of liposomes and an increase of 22% of target site accumulation. A recent study 
reported the co-embedding losartan and anti-cancer drugs (DOX) into hollow mesoporous 
prussian blue NPs (HMPBs).[109] The drug losartan was released at the fixed point of the tumor 
tissue triggered by an NIR laser. The results illustrated that losartan can degrade the collagen I 
in ECM and triple the accumulation of DOX in tumor tissues (increase from 0.49% to 1.47% 
of the injected dose). Consequently, such studies confirmed that losartan has a penetrating-
enhancing effect on NPs or co-delivered drugs. A most recent study proposed that using nitric 
oxide (NO), an endogenous free radical, can also degrade collagen in the ECM without 
introduction of toxic component.[110] The depletion mechanism was that NO has the ability to 
induce the activation of MMP-1 and -2, which can functionally disintegrate the tumor matrix 
collagen. In vivo study showed that NO treatment led to around 2-fold increase of DOX 




Furthermore, degradation of the ECM can also be achieved by functionalizing NPs 
with enzymes that degrade tumor ECM components. An example is coupling of hyaluronidase, 
which degrades hyaluronan – one of the main components of the ECM – to NP surface to enhance 
tumor penetration. The in vivo and in vitro studies carried out by Gong et al. in 4T1 tumor 
models illustrated that enzyme-modified NPs achieved significantly greater tumor penetration 
depths and thus overall drug delivery efficacy, in comparison with their hyaluronidase-absent 
counterparts.[111] Additionally, such coupling also reduced the IFP, thus further establishing 
uniform distribution of NPs inside tumor tissue.[58] This is particularly important in some types 
of tumors such as pancreatic ductal adenocarcinoma (PDAC).[112] This cancer has extremely 
low survival rate due to its nearly impenetrable ECM, and pancreatic stellate cells (PSCs) are 
the main culprit for this phenomenon. For better treatment, Han et al. reported that dual 
delivery of all-trans retinoic acid (ATRA, to trigger PSC quiescence) and heat shock protein 
47 (HSP47 siRNA, a collagen-specific molecular chaperone for the regulation of ECM 
network) to PDAC via Au-NPs carriers induced effective reduction of ECM, correspondingly 
resulting in enhanced chemotherapy efficacy both for in vitro and in vivo tests.[112] In addition, 
as Zhang et al. reported, cyclopamine also showed the ability to modify the excessive 
desmoplastic ECM of PDAC.[113] 
Moreover, as described above (Section 2.2.3), stromal cells in tumor 
microenvironment perform unwanted uptake of drug NPs and induce fibrosis that impede 
penetration of nanomedicines into deep cancer cells. Thus, targeting and depleting these 
matrix cells is also significant to the breakage of stromal delivery barrier and improve the 
intratumoral penetration of therapeutic NPs.[114-115] Many specific receptors expressed by 
stromal cells (e.g. FAP, FAK, FGFR and CXC-chemokine receptor 4) and strategies for 
targeted clearance of these stromal cells have been widely reported.[116-119] Ji et al. reported 
using amphiphilic peptide (C2KG2R9)‐cholesterol self-assembled NPs loaded with DOX 




CAFs.[120] This design fulfilled the aim of targeting, penetration and therapy. The mAb can 
specifically bind human fibroblast activation protein‐α (FAP‐α) which is selectively expressed 
by CAFs but not in normal cells.[121] The results of in vivo tests indicated that after treatment 
with PNP‐D‐mAb, the typical morphology of CAFs in mice tumors disappeared. The 
percentage of apoptotic cancer cells in PNP‐D‐mAb groups (60%) was much higher than that 
in the control (5%) and PNP-D (17%) groups. Miao et al. found that after repeated treatment 
with cisplatin, the expression of Wnt16 in CAFs was elevated, leading to drug resistance. In 
this case, anti-Wnt16 siRNAs was combined with NPs to target Wnt16 in fibroblasts to kill 
them.[122]    
Except using chemicals or enzymes, the degradation of ECM can also be achieved by 
several external physical energy, for instance, ultrasounds, light and magnetic field (Table 6). 
Lee et al. applied a high intensity focused ultrasound (Pulsed-HIFU) to ECM-rich A549 tumor 
tissues. The results showed that it largely reduced the amount of collagen and hyaluronan in 
ECM, thereby the intensity of NPs in treated tumor tissues has increased 2.18-fold than that 
in untreated tissues.[123] .  
3.2.2 Vascular normalization 
The interaction between the disorganized vascular networks in tumors and the abnormal tumor 
microenvironment can result in increased IFP; consequently, this prevents adequate and 
homogeneous blood flow and, therefore, impedes deep penetration of NPs in tumors.[79] 
Therefore, normalization of tumor vasculature has become an increasingly popular method to 
improve the drug delivery efficacy of NPs. The process of vessel normalization transforms the 
abnormal phenotype of tumor vessels into those which resemble fully functional, cancer-free 
vessels; this is achieved by repairing the basement membrane, increasing the coverage of 
pericytes and thus decreasing the extravasation of the tumor vasculature. Doing so has the 
advantageous effect of lowering the IFP and thus increasing tumor blood flow, which 




proangiogenic molecules, such as vascular endothelial growth factor (VEGF), fibroblast growth 
factor (FGF), and platelet-derived growth factor (PDGF), are overexpressed, ultimately 
resulting in a chaotic tumor vessel structure to develop. Consequently, it is desirable to be able 
to block these proangiogenic signaling molecules in order to repair tumor vessels.[47] 
Chanhan et al. showed that the delivery of small NPs (12 nm diameter) could be 
enhanced by repairing the abnormal tumor vessels in mammals.[124] This was achieved by 
blocking VEGF receptor-2 with an antibody, DC101. Nevertheless, such a procedure only 
enhanced tumor penetration of NPs with 12 nm in diameter and the larger NPs (125 nm 
diameter) could not benefit from this approach.[45] This was due to the fact that DC101 
decreases tumor vessel pore size and thus reduces IFP, which facilitates the convective 
permeation of small NPs and hinders the extravasation of larger NPs. Conclusively, such results 
further emphasize the fact that smaller NPs tend to achieve greater drug delivery efficacy and, 
therefore, are considered more efficient cancer treatments due to their ability to reach greater 
tumor penetration depths.[124] 
Cyclooxygenase-2 (COX-2) is highly expressed at the tumor regions and it is actively 
involved in diverse cancer types for dense ECM formation and angiogenesis.[125] Thus, applying 
COX-2 inhibitors could be an effective tool to normalize tumor microenvironment including 
both ECM damage and vascular normalization functions. Kim et al. reported indomethacin 
(IMC) can produce effective angiogenesis inhibition via COX-2 blockade.[126] Zhang et al. 
reported a COX-2 inhibitor, Celecoxib, to disrupt ECM and reduce tumor-associated fibroblast 
and normalize tumor vessel on A549 tumor xenografts (Figure 12).[127]  
3.2.3 Vascular disruption 
Intratumoral transport of NPs can be improved by enhancing the permeability of tumor vessels, 
i.e. transvascular transport; this varies significantly between different tumors and is 
heterogeneous within the same type of tumor and at the same stage of development. The 




succeeded by a brief eruption of fluid into the tumor interstitial space. Smaller NPs (30 nm) are 
more easily distributed throughout the tumor as they can utilize both the eruption and static 
permeability stages, whereas larger particles rely on the dynamic eruption alone.[48] 
As a consequence, vascular disruption can be achieved by pre-treatment with vascular 
disrupting agents (VDA), or radiation, ultrasound, and NIR laser irradiation, in order to enhance 
the permeability of tumor vasculature and thus improve intratumoral transport of NPs.[128-130] 
CA4P is a potent VDA which can cause endothelial damage by elevated serotonin and nitric 
oxide (NO) production. Studies have shown that greater tumor penetration depths are reached 
by NPs conjugated with CA4P. Satterlee et al. investigated and documented that co-injection 
of CA4P with lipid-platinum-chloride NPs led to accumulation of NPs in tumor vessels in 
mice.[131] They observed a clear vascular disruption effect in UMUC3/3T3 and 4T1 tumors, and 
target NP accumulations increased from ~1.2 to 2.1 injected dose%/gram and from ~2.5 to 3.2 
injected dose%/gram for the two models, respectively. Such a study, amongst many others, 
strongly supports the fact that VDA are capable of enhancing the permeability of tumor vessels 
and the tumor penetration depths reached by NPs. However, the efficacy of VDA is 
compromised by their toxicity and the side effects that they can cause. Nonetheless, physical 
encapsulation or chemical conjugation of VDA in nanocarriers has the potential to overcome 
these negative effects and thus increase their clinical potential.[45] 
Theek et al. showed one example of using ultrasound to induce vascular disruption and 
improve the penetration of 133-nm liposomes[132] Microbubbles were injected with liposomes 
at the same time, under the effect of ultrasound, the oscillation produced by microbubbles can 
open the tight junctions in vascular endothelium (sonoporation).  Upon sonoporation, the 
relatively large liposomes (above 100 nm) can also cross out of the blood vessels and penetrate 
into the tumor interstitium, and around 60% of liposomes were found in the 10 μm region 
surrounding the vascular wall and around 20% of them reached 50 μm from the vessels. 




plays a role in the ECM production, angiogenesis and metastasis.[133] Several TGF- β inhibitors 
(TGF-β-I) have been proved to prevent some cancers from metastasizing.[134] Moreover, their 
functions to improve vascular permeability were also been explored. Cabral et.al reported that 
the TGF- β inhibitor can lessen the pericyte coverage of the tumor endothelial wall and increase 
the penetration of NPs.[135] They first compared the penetration properties of 30 nm and 70 nm 
micelles in mice BxPC3 xenografts. At 1 h post-injection, the 30 nm micelles had been 
apparently observed in cancer cells that are 40 μm from blood vessels while the 70 nm micelles 
still remained near the vasculature without further penetration to the interstitial space. This 
results reflected that size is a pivotal characterization to govern the tumor penetration of NPs. 
However, when the mice in the 70 nm micells group were pre-treated by a low dose (1 mg/Kg) 
of TGF-β-I (LY364947), the results became completely different. The tissue penetration ability 
of 70 nm micelles was augmented to a similar level compared with that of 30 nm micelles. At 
24 h post-injection, both of them were detected at 100 μm from the blood vessel and displayed 
comparable subcellular localization. 
 In conclusion, vascular disruption can be utilized in order to enhance tumor vessel 
permeability and thus improve NP penetration within tumor tissues. On the other hand, vascular 
normalization can increase blood perfusion and lower the IFP, which consequently promotes 
convective diffusion of NPs in tumor tissues. Nevertheless, vessel pore size can be reduced by 
such a strategy which hinders the penetration of larger NPs. As a result, the tumor vasculature 
should be carefully monitored and regulated in order to achieve an optimal balance which 
enhances tumor vascular permeability and blood perfusion, thus promoting intratumoral NP 
transport. 
3.2.4 Hypoxic normalization  
The hypoxia region located in the deep tumor is absent of blood vessels.[136-138] Eventually it 
reduced penetration of systemically administered nanomedicines to this region. In addition, 




central to tumor growth, metastasis and treatment.[139] Increasing the oxygen concentration in 
hypoxic region is crucial for the diffusion of NPs in solid tumors.  
One view is that hypoxia is associated with the active activity of mitochondria‐
associated oxidative phosphorylation (OXPHOS). Xia et al. reported gelatin-based NPs 
containing FDA (U.S. Food and Drug Administration) approved OXPHOS inhibitory drug, 
atovaquone (Ato), to transform hypoxia to normoxia. The NPs exhibited size shrinking (from 
437 to 14 nm) under tumor microenvironment observation because of the degradation of gelatin 
coating by MMP-2 enzyme and followed release of Ato in the deeply hypoxia regions.[140] Other 
OXPHOS inhibitory drugs have also been reported including metformin and papaverine.[141-142] 
Another view proposed by Milotti et al. is that the shortage of oxygen concentration in tumor 
could be largely due to the low-frequency oscillations of arterial circulation,[143] while they 
found that a type of antihypertensive drug, alpha-blockers, can reduce or even abolish this low-
frequency rhythms and result in enhanced diffusion of oxygen in solid tumor.  
Moreover, Chlorine e6 (Ce6) is a kind of photosensitizer, used for fluorescence imaging, 
but it can generate singlet oxygen (1O2) when it is activated by light.[144-145] Min et al. attached 
Ce6 to the gemcitabine (GEM) eluting polyurethane (PU) membrane.[146] After exposure to 671 
nm laser at 80 J/cm2, the tissue penetration efficiency of GEM increased 2-fold and the tumor 
volumes in Ce6–GEM–PU + light group is 3-fold smaller than that in the group treated with 
Ce6–GEM–PU but without light exposure. Qian et al. reported a new photosensitive moiety as 
well as NIR imaging agent, dithiophene-benzotriazole, which can also produce 1O2 under the 
activation of visible/near‐infrared (Vis/NIR) light. [147] Then they combined it with the 2‐
nitroimidazole to perform subsequent drug release in hypoxic cells (Table 6). Some proteins, 
such as human ferritin nanocages (FTn), were reported to have intrinsic ability to penetrate to 
the hypoxic region of tumor.[148] To enhance the colloidal stability of FTn, Huang et al. 
engineered a unique spatially controlled PEG coating to FTn (PEG-FTn75%) instead of 




the exposure of FTn and resulted in the capable of delivering chemotherapeutic drugs to the 
hypoxic lung tumor tissues in vivo (Figure 13a). At the 18 h after the administration, the amount 
of PEG-FTn75% found in hypoxic tumor regions was significantly higher than that of non-
PEGylated FTn (Figure 13b, c). 
3.3 Magnetic field for deep penetration 
Tumor hypoxic regions show high resistance to the pharmaceutical nanocarriers 
penetration and to radio or laser beams spread.[150] Thus, beyond the addition of anti-hypoxia 
drugs to nanosystems, extra external propelling forces, such as magnetic and acoustic forces, 
are widely considered to promote the penetration of nanomedicines to deep hypoxic cancer 
cells.[151] Among them, the magnetic force occupies the incomparable position since its spread 
is barely affected by hypoxic regions and its low toxicity. Magnetic NPs (MNPs) have been 
approved for the clinical use for the generation of hyperthermia to control drug release under 
dynamic magnetic field, for example, NanoTherm®. Moreover, there is a strong preliminary 
evidence indicating that the external magnetic field can direct the delivery of drug-loaded 
MNPs to tumor sites.[152-154] Thus, recently, magnetic fields including static magnetic field and 
dynamic magnetic field with corresponding MNPs are gaining popularity in assistance of 
nanomedicines for tumor deep penetration.   
For deep penetration, MNPs must show high magnetic saturation, biocompatibility and 
biodegradability. Commonly used MNPs are superparamagnetic iron oxide (Fe3O4 and MFe2O4 
(M=Mn, Co and Zn)) which are widely existing in microorganism (bacteria and fungus) and 
can be synthesized in the laboratory. For example, Felfoul et al. used magnetotactic bacteria, 
MC-1 (naturally contains a chain of magnetic iron-oxide nanocrystals), as the drug carrier.[155] 
The results showed that more than half of MC-1 cells have crossed peritumoral regions and 
penetrated into hypoxic regions of colorectal xenografts under a directional three-dimensional 
magnetic field. Guo et al. examined the penetration depth of different sized Fe3O4 NPs (60, 120, 




respectively.[156] Shamsi et al. constructed a computational model for numerical evaluation of 
the interstitial penetration efficiency of drug-loaded MNPs (200 nm) in the medium (R = 5 mm) 
and large (R = 10 mm) sized peritoneal neoplasms against dense ECM and high IFP (Figure 
14A,B).[157] It was believed that the magnet strength and the distance between tumor and magnet 
are critical for successful penetration of MNPs in large tumors while there is less concern in 
small tumors. 
In addition to strong rare earth magnets and electromagnets, the primary sources of 
external magnetic fields, magnetic resonance imaging (MRI) scanner was reported to be an 
alternative magnetic field generator for MNPs directing by Muthana et al.[158] Each MRI 
scanner contains inherent magnetic field coils, but the magnetic field is homogeneous without 
orientated propelling function. Hence, in this study, they supplied a 300 mT m−1 gradient coil 
to the 7 T MRI system to generate substantial actuation forces on MNPs loaded macrophages. 
They investigated its efficiency in a novel transendothelial migration flow model (Figure 14C). 
The results indicated that this magnetic field gradient (MRT) can steer magnetic macrophages 
across vascular endothelial layer against the blood flow shear force and fully penetrate into 
human multicellular tumor spheroids after 1h application (Figure 14D). The success of this 
study is meaningful because MRI is also a significant tool to diagnose and image cancer. It 
provided an opportunity for concomitant imaging and therapy of tumor.  
Except being used as this navigation strategy, Schuerle et al. provided a novel approach 
to utilize the magnetic attraction between magnetic fields and MNPs for achieving deep 
penetration of nanomedicines.[159] Without the help of external forces, the convection and 
diffusion are two main approaches that NPs were used to penetrate within the tumor. Thus, they 
engineered two types of magnetic micropropellers powered by rotating magnetic fields (RMFs) 
to enhance diffusive transport of NPs. The one is natural magnetotactic bacteria (MTB) and the 
other one is magnetic artificial bacterial flagellum (ABF). Under the influence of a rotating 




propulsion and increased convective flow in the surrounding fluid in a microfluidic model. 
More importantly, these magnetic micropropellers are compatible with a wide range of NPs 
because the method just required simple mixing magnetic NPs and medicine NPs.[159]  
3.4 Biological and biomimetic nanocarriers for deep penetration 
Apart from using diverse laboratory-made functionalized organic, inorganic and polymeric 
NPs, some naturally occurring viruses and cells can exhibit intrinsic tissue penetrated 
properties.[160-161] The natural mission of animal virion NPs is to deliver their genes and 
accessory proteins into potential host cells. Viral protein transduction domains (e.g. 11–amino 
acid protein form HIV Tat) enable them to achieve a series of delivery activities in host cells, 
including penetration of mucus layers, fast cellular membrane attachment, endocytic entry, 
efficient tissue penetration and final nuclear import.[162-163]  It is worth noting that for viruses, 
acidic pH (pH 6-6.5) in endosomes is an essential trigger for penetration and uncoating (release 
of viral genomes).[164] This trigger condition exactly matches with the acidic tumor 
microenvironment. Besides, some immune cells are able to migrate across impermeable barriers 
and unload their cargo at infected sites.[165]  For instance, neutrophils (NEs), the most common 
type of immunocytes, have been widely used in brain-targeted drug delivery because of their 
native abilities to cross the blood–brain barrier (BBB) and penetrate glioma.[166-167] Thus, the 
biological or biomimetic nanocarriers may surpass other nanocarriers in some tumor types and 
be a breakthrough to deliver cargos to deeper cancer cells.  
Zhang et al. produced virion-like NPs, 2, 3-dimethylmaleic anhydride decorated tumor-
activated arginine-rich dendritic peptide prodrug (DA-Dend‐ R4K2K‐ Hyd‐DOX) NPs 
(average size of 136.3 ± 5.8 nm), which mimicked both the natural protein transduction domains 
and dendritic arginine-rich virus-like architecture to acquire intrinsic multivalent effect to 
increase tissue and cell dual-penetration.[168] After confirming that virion-like NPs can 
recognize the tumor-specific acidic pH microenvironment in a biomimetic biphasic model 




SKOV3/R cancer cells in 3D µ-slide chamber with matrigel to ensure the incubated conditions 
much closer to the real tumor microenvironment. The confocal fluorescence microscopy images 
showed that the viron-like NPs penetrated more than 600 μm. Xue et al. used NEs as the drug 
carriers to encapsulate paclitaxel loaded liposomes (PTX-CL/NEs).[167] The inflammatory 
factors (interleukin-8 and tumor necrosis factor) can direct the movement of PTX-CL/NEs 
toward brain tumor. The results of mice treatment showed that the PTX-CL/NEs treatment 
increased the 50% survival rate of up to 61 days, while this value for PTX-CL treatment was 
only 38 days. 
4. Discussion 
4.1. Advantages and disadvantages of different strategies for deep penetration of 
nanomedicines 
The use of nanotechnologies to target tumors with deep penetration depth for efficient cancer 
treatment has been a main source of attention for researchers in recent years. This is a result of 
their potential ability to overcome several limitations related to conventional chemotherapeutic 
drug formulations. They offer: (1) enhanced drug loading capabilities, (2) ability to protect 
enclosed drug molecules from physiological hazards, (3) ease of adaptability to passive and 
active targeting, (4) multi-functionalization, and (5) improved biocompatibility. Consequently, 
it comes as no surprise that nanomedicine is regarded as a fast growing area of research in the 
world.  
However, in the context of clinical cancer therapy, due to the biological barriers of 
tumors, these nanomedicines are usually accumulated at the invasive edge of the tumor, with 
inability for further penetration, so the tumor cells loaded in the necrotic inner layers of tumor 
are often untreated and cause, causing tumor recurrence. Thus, the most difficult barrier that 
nanomedicine engineers need to overcome is that of achieving great tumor penetration depths. 
To address this, nanomedicines are designed to facilitate tumor interstitial transport, such as 




caused a following problem since the requirement in each transport stage is different. The above 
design does increase the penetration depth, but at the expense of pharmacokinetics, limiting 
their accumulation at tumor sites. As a consequence, in order to overcome such a problem, four 
significant options exist: dynamic fine-tune the physico-chemical properties of NPs, remodel 
the tumor microenvironment, use external sources of energy (e.g., magnetic force), or adopt 
biological and biomimetic nanocarriers.  
These strategies can be further broken down into more precise categories. In the context 
of dynamic fine-tuning the physico-chemical properties of NPs, this can be done through 
intratumoral regulation of particle size, shape and/or surface biochemistry. Modifying each of 
these properties individually has a significant effect on the resulting penetration depth achieved 
by NPs within tumors; however, this effect can be further increased by optimizing such 
properties concurrently. NPs can be engineered in such a way that these properties can undergo 
changes triggered by internal or external stimuli, including pH, overexpression of enzymes, 
redox, hypoxia, light, ultrasound and temperature. Such a feature is highly desirable for NPs as 
it enables them to exhibit multiple properties which, consequently, allows for maximum drug 
delivery efficacy to be achieved. Resultantly, stable, programmed NPs circulating in the blood 
are activated upon arrival at the specific tumor site and thus are able to reach greater penetration 
depths. In addition to the control of above features, tuning the membrane rigidity was reported 
to be a potent strategy for improving the tumor penetration ability of liposomal NPs. Yuki et al. 
quantitatively demonstrated the rigidity (bending modulus (Kc)) of liposomes and they found 
there is a positive correlation between the rigidity and permeability of liposomes in the solid 
tumor.[169] In a recent study, Zhang et al. illustrated the huge influence of NPs surface 
architecture on intratumoral penetration.[170] 
Except controlling the properties of NPs for deep penetration, the tumor 
microenvironment can be remodeled in a number of ways, including degradation of ECM, 




Vascular normalization can increase blood perfusion and lower the IFP which promotes 
convective diffusion of NPs in tumor tissues. On the other hand, vascular disruption can 
enhance tumor vessel permeability and thus improve NP penetration within tumor tissues. Thus, 
an optimal balance which enhances tumor vascular permeability and blood perfusion should be 
better determined. For example, the normalization of tumor vessels may cause the compromise 
with the EPR effect. Conclusively, the tumor vasculature modulation requires careful 
monitoring and regulation in order to achieve deep penetration of NPs. 
Overall, the above two strategies have promoted tumor penetration of nanomedicines to 
varying degrees and improved therapeutic efficacy, but they are still associated with several 
problems, which restrict their further clinical development. For the strategies of internal triggers 
induced NPs properties change and modulation of tumor microenvironment, one limitation 
should be highlighted is the heterogeneity associated with tumor growth. It can vary between 
different tumor types, individual patients, of course, would differ greatly between species. 
Mouse tumors, although grown with humans in mind, would exhibit size and growth variations. 
This certainly raises a question into current research in these two strategies because their effects 
are highly influenced by tumoral types and patients. Proven techniques in mice are probably 
not successful in humans. Another disadvantage is that the design and synthesis of this kind of 
smart NPs are relatively complex, requiring elegant control of the physico-chemical properties 
of NPs under different conditions.  In contrast, for external triggers induced properties change, 
such as laser radiation beams and ultrasound, their treatments less lie with the heterogeneity of 
the tumors between patients, and thus they are more likely to achieve clinical translation. Their 
significant disadvantages are their responses would be largely reduced in tumor avascular zones 
(oxygen free) and their working areas are rather localized. They cannot administer tumor 
systemically and show limited therapeutic efficacy for metastasized lesions. However, the 
advantage of the approaches in this category is that they minimize the disruption to patients’ 




may stimulate the movement of tumor cells, and result in cancer metastasis. This situation could 
be explained that degrading the dense ECM will break the collagen network and cell-matrix 
combination, thus causing the bidirectional penetration of the cancer cells. In other words, while 
damaged ECM makes nanomedicines easier to penetrate, it facilitates the leaking out of the 
surviving tumor cells from the vascular endothelium (endothelial leakiness) meanwhile, thus 
cancelling out the treatment effects. One example was reported by Peng et al. in this year.[171] 
Therefore, special consideration should be given to the strategies that remodel the tumor 
microenvironment for enhanced drug delivery.  
Based on these problems, supplemented strategies that use magnetic pulling force or 
intrinsic tissue penetrated properties of viruses and cells to increase nanomedicines penetration 
depth have been reported. Particularly, magnetic force has been widely investigated recently 
for three reasons. First, the oxygen-free condition will not affect the spread of magnetic force, 
and it could exhibit great outcomes in vivo because it is independent of heterogeneous between 
different tumors and patients, and pathological properties of tumors. Second, compared with 
laser beams manipulation, magnetic field shows less damage to healthy cells. Third, it has the 
potential to treat metastatic tumors because MNPs can be injected systemically. Muthana et al. 
have shown their magnetic system can target both primary and secondary metastatic tumors in 
mice test.[158] However, the question of this strategy is that whether the magnetic force is 
sufficient to allow drug-loaded MNPs to perform interstitial transport and whether it will 
aggravate tumor local heterogeneous resistance. And to clinical translation, the ability to 
provide the same magnetic propelling force to human is still being studied. 
4.2. Integration of different strategies for improved outcome  
Each of the above described penetration strategies boasts its own advantages and 
disadvantages for different applications and, therefore, further research is required into the 
specifics of each one. For the same reason, as discussed in our previous review, a natural design 




effect.[172] Many researches have been reported and some recent examples are listed in Table 7.  
Additionally, the improvement of penetration of NPs in tumor tissues is not only good 
for enhancing cancer treatment efficacy but also useful for tumor imaging and diagnosis.[173-175] 
Zhou et al. created multi-responsive nanocarriers for treatment of triple-negative breast 
cancer.[90] The NPs decreased the size in the tumor microenvironment through contacting with 
MMP-2. Pheophorbide a (PPa) caused mild-hyperthermia with NIR radiation and it also 
enabled the NPs to be suitable for imaging. In the meantime, the NPs induced reactive oxygen 
species (ROS) generation to aid photodynamic therapy (PDT). Overall, these NPs are enzyme, 
light and heat sensitive with imaging capacity. Qian et al. designed a smart multi-peptides 
functionalized nano delivery system named as STD Nano-micelle (NMdrug).[176] This delivery 
system contained five functional elements for the simultaneous achievement of cancer 
diagnosis, tumor targeting therapy and enhanced tumor penetration. In brief, the five 
components are peptide STP (sequence: SKDEEWHKNNFPLSPG) for pH-triggered target, a 
caspase-3 triggered peptide linker (sequence: DEVD), TPE (tetraphenylethylene) which 
exhibits ‘switch on’ fluorescence during apoptosis, cell-penetrating peptides TAT and DA (2,3-
dimethylmaleic anhydride) for shielding the cation on TAT. As a result, the STD-NM 
performed in a stealth state in the blood circulation because of the DA, and then only in the 
tumor site, the STD-NM could be switched to the activated state. The acidic pH stimulated STP 
and TAT for enhanced cell permeability and caspase-3 stimulated DEVD and TPE for 
fluorescence imaging of cancer cells (Figure 15).  
Wang et al. reported a complex therapeutic nanoplatform, ATLP, which took advantage 
of three strategies (size shrinking, surface chemistry and ROS generation) and both internal and 
external stimuli for the tumor-targeted deep penetration.[177] The ATLP NPs consisted of a Ce6 
modified PEG-b-poly(2-(hexamethyleneimino) ethyl methacrylate) shell (termed as PHMA) 
and an amphiphilic iRGD-GALGLP-P85-PLGLAG-DOX core (termed as iPAPD). First, in the 




from amphiphilic to hydrophilic resulting in its detachment from iPAPD. As a result, the iRGD 
and Ce6 were exposed to facilitate tumor-targeted penetration and real-time fluorescence 
imaging, respectively. The fluorescence signal of NPs at pH 6.6 is 3.4 times higher than that at 
pH 7.4 (Figure 16A). Second, the MMP-2 enzymes triggered further intratumoral drug release 
of DOX via the cleavage of MMP-2-labile peptide, PLGLAG. Third, the external stimulus, NIR 
laser was employed to enhance intratumoral DOX diffusion by inducing Ce6 (also a 
photosensitizer) to produce ROS inside tumor. The results showed that the intratumoral DOX 
accumulation in iPAPD groups is 3.5-fold higher than that in free DOX groups (Figure 16B) 
and iPAPD + laser treatment completely eliminate the mice tumor xenograft (Figure 16C).  As 
a result, this study provided an effective approach to combine multi strategies into one 
nanoplatform and fulfilled the purpose of theranostics simultaneously. More recent examples 
are summarized in Table 8. 
So far, since extensive researches have been studied in using these individual 
approaches and their combinations for cancer treatment and imaging in animal models and 
promising outcomes have been achieved. With these findings as the basis, future research 
should be directed towards improving the clinical relevance and translational feasibility of these 
technologies, which is also the ultimate challenge of nanotechnologies in tumor deep 
penetration application. NPs that prove successful in vivo testing on animals hardly reaches the 
same conclusions in humans, and post successful trials NPs must be able to be reproducible, 
scalable and manufactural for worthwhile commercialization. Simpler, one-stage NPs could 
possibly be made with current pharmacology unit operations, while the much more complex 
NPs described throughout this review will require innovative techniques, consequently adding 
years to their mass productions and public release. 
4.3. How deep is deep? 
As of June 2019, using ‘(nanoparticles/liposomes/micelles) AND (cancer/tumor)’ as the search 




decrease to 2675 when adding an extra keyword ‘penetration’. The results reflected the fact 
that, for decades, around 95 percent of researches on nanomedicines was focused on increasing 
accumulation of free drugs to tumor sites by taking advantage of nano size (first- and second-
generation NPs), but often few of them have looked at further tumor tissue penetration 
improvement. Therefore, at present, the production of penetration facilitated NPs (third-
generation NPs) can be considered as a proof-of-concept study, and which is still staying in the 
laboratory test phase. To determine its future pathway, the progress that the current researches 
have carried out should be rigorously investigated. 
To prove the validity of these NPs in tumor penetration, their depth-of-penetration 
should be evaluated as an important parameter. For the assessment of NPs penetration in vitro, 
a significant mass of studies chose cancer cell-seeded collagen scaffold, 3D tumor multicellular 
spheroids and microfluidic tumor model rather than monolayer cells.[178-180] This is because 
these models can better simulate the real transport conditions in tumor extracellular matrix and 
tumor microenvironment.[181] Tumor spheroids are able to form specific penetration barriers 
(e.g. hypoxia, proliferative gradients and control of certain ECM components) when their sizes 
beyond 350 μm.[182] The microfluidic tumor model is an upgraded model that supplies the 
simulation of endothelial cellular layer, local tissue-tissue interfaces and blood flow to test the 
targeting, extravasation efficacy and penetration of NPs against blood flow shear force or 
interstitial flow, some examples mentioned above.[183-184]  
For in vivo evaluation, xenograft mice tumor models have been frequently used. The 
penetration depth of NPs in the mice models is a crucial datum to predicate their clinical 
performance. As displayed in Figure 17, 21 publications were found to have quantitative data 
of the penetration depth of NPs from the tumor vessel (intravenous injection). The used 
penetration strategies in these publications include size/charge switch, surface chemistry 
decoration, modulation of tumor microenvironment, ROS generation and biological delivery 




μm in colon tumor via the combined strategy of size reduction and ROS generation and the 
work was published in 2019.[185] However, in most of the work, the penetration of NPs is below 
200 μm.  The mean and median of penetration depth of the evaluated penetration depth is 
approximately 130 and 90 μm, respectively. When the penetration depth is measured from the 
tumor periphery, the values can reach up to 2 millimetre level in some studies.[63, 186-187] One 
novel strategy was using repeated intra-intercellular delivery for enhanced penetration of 
DOX.[186] This was achieved by the construction of monostearate protected DOX preloaded 
amorphous calcium carbonat (MS/ACC–DOX) NPs. The high aqueous instable amorphous 
calcium carbonat (ACC) NPs can achieve burst release of DOX in cancer cells, and after 
inducing death of one cell, they can move to the next cell and repeat the drug release process, 
like peeling an onion layer by layer (Figure 18). This strategy allows the loaded drugs to have 
more chances to reach the cells near the tumor core. However, if comparing this penetration 
depth with the real size of many tumor tissues, it is apparently insufficient.  
As a result, it can be expected that fulfilling the whole tumor penetration in the human 
body will not be an easy goal, based on current data. Besides, although researchers have testified 
their multifarious strategies can improve the penetration of NPs or drugs in in vitro or in vivo 
models at varying degrees, their outcomes in clinical setting remain to be determined. For 
example, the size, stage and location of tumor and the specific barriers for different tumor types 
and individuals are different. All of these factors could have an outsized impact on the 
behaviour of NPs in thebody. It is often that the design of NPs for deep penetration is complex, 
imposing great difficulty in obtaining approval.    
4.4. Potential of immunotherapy to boost the effect of nanotherapeutics 
As described above, the tumor penetration facilitated NPs seem to have a bleak prospect in 
killing all tumor cells. In this circumstance, the future direction of nanomedicines needs to be 
carefully rethought beyond simply aiming for deeper and deeper penetration depth. For example, 




improved penetration. In fact, the immunotherapy and deep penetration NPs could build a 
mutually beneficial relationship by two strategies.  
First, using nanocarriers to establish a ‘specific-drug reservoir’ in the vicinity of the 
tumor matrix and kill some tumor cells. It could be sufficient to induce immunogenic cell death 
(tumor immunity) and then the T cells, especially cytotoxic CD8+ T lymphocytes (CTLs) can 
kill inner chemotherapy-resistant cancer cells (Figure 19).[188] Thus, in this case, penetrating 
whole tumor tissues is not always needed. Krysko et al. pointed out that the ability of a cancer 
therapy to produce ROS and endoplasmic reticulum (ER) stress (either in parallel or in tandem) 
determines whether it can induce immunogenic cell death.[189]    
Second, delivery of cytotoxic T lymphocyte protein 4 (CTLA4) inhibitors or 
programmed death-ligand 1(PD-L1) inhibitors to the tumor sites is an alternative strategy to 
initiate antitumor immune response via the break of tumoral adaptive immune response or 
immune evasion.[188] Apart from innate immune cells (e.g. macrophages, dendritic cells and 
neutrophils) in the tumor microenvironment, T cells (i.e. T and B lymphocytes) take the main 
responsibility of suppression and control of tumor growth.[190] But tumor seems like a ‘clever’ 
organism which can develop the self-protecting mechanism to against their attacks.[191] CLTA-
4, as well as PD-L1 and its receptors (programmed cell death protein 1, PD-1) are significant 
immune checkpoint molecules in the associated process. For example, many tumors will 
overexpress PD-L1 to specifically bind PD-1 which expressed on the surface of T cells and then 
induce the apoptosis of T cells. In this case, using PD-L1 or CTLA inhibitors to stop the 
resistance of tumor seems to necessary and promote T cell priming, and the tumor regression 
effect of this checkpoint blockade therapy has been proved in a range of malignant tumors (e.g. 
lung, ovarian, bladder, melanoma and colorectal cancer) and many immune checkpoint 
inhibitors have been approved by FDA.[192-193] Therefore, consideration of adding these 
components into the design of NPs could be a promising way as only tiny tumor penetration 




photodynamic therapy (ROS generation) and PD-L1 gene silencing, with deep penetration NPs 
for cancer treatment.[61] PD-L1‐blockade siRNA (siPD-L1) and a photosensitizer, MTPP (5‐(3‐
Hydroxy‐p‐(4‐trimethylammonium)butoxyphenyl)‐10, 15, 20‐triphenylporphyrin chlorine) 
were encapsulated into the size and charge changeable pH-responsive micelleplex (denoted as 
PCPP). PCPP protected the drugs during blood circulation and its property change ensured 
siPD-L1 and MTPP to penetrate to a considerable depth in the tumor microenvironment. At 2 
h post-injection into the B16F10 tumor‐bearing mice, PCPP@MTPP@siPD‐L1 could be 
detected at a tumor depth at 300 µm. Then the highly positively charged PCPP were 
disintegrated in the pHi to release the cargos. The results showed that after cargo release, the 
level of CD8+ T cells and helper CD4+ T cells in tumor had a 10-fold and 7-fold increase, 
indicating successful activation of immune response in vivo. In the following antitumor test, 
the PCPP@MTPP@siPD‐L1 + irradiation group can eliminate almost all tumors (via tumor 
volume analysis) after treatment for 18 days, and the survive rate was 83% after 30 days. 
Moreover, the activated immune effect largely decreased the tumor recurrence rate from 100% 
(control and PCPP@MTPP groups) to 25% after 28 days.  
5. Conclusion 
In conclusion, nanomedicine represents one of the fastest growing research areas and is 
considered to be one promising therapy for treating cancer with deep penetration. This review 
has highlighted the delivery problems associated with nanotechnology, which is partially 
hindering the translation of nanomedicine in clinical cancer treatment. Several strategies to 
balance all of the requirements of drug transport in blood circulation, tumor targeting and tumor 
penetration have been discussed. However, like many other scientific advances that have 
recently revolutionized, nanomedicines must be further developed to be mature before their full 
impact can be realized and taken advantage of. The delivery process, which is extremely 
complicated and governed by numerous factors, must be capable of overcoming a range of 




future, studies must address the challenges to tackle tumor heterogeneity, incorporate 
immunotherapy in nanomedicines, and conduct clinical studies to validate new strategies in 
patients. 
Acknowledgements 
((Acknowledgements, general annotations, funding. Other references to the title/authors can 
also appear here, such as “Author 1 and Author 2 contributed equally to this work.”)) 
 
Received: ((will be filled in by the editorial staff)) 
Revised: ((will be filled in by the editorial staff)) 






[1] M. Roser, H. Ritchie, Cancer, https://ourworldindata.org/cancer, accessed: July, 2019. 
2019. 
[2] S. M. Sagnella, J. A. McCarroll, M. Kavallaris, Nanomedicine 2014, 10, 1131-1137. 
[3] X. F. Chen, W. J. Zhang, Chem. Soc. Rev. 2017, 46, 734-760. 
[4] R. Chen, J. F. Zhang, Y. Wang, X. F. Chen, J. A. Zapien, C. S. Lee, Nanoscale 2015, 7, 
17299-17305. 
[5] J. F. Zhang, Y. N. Li, F. F. An, X. H. Zhang, X. F. Chen, C. S. Lee, Nano Lett. 2015, 
15, 313-318. 
[6] L. Yan, W. Chen, X. Y. Zhu, L. B. Huang, Z. G. Wang, G. Y. Zhu, V. A. L. Roy, K. N. 
Yu, X. F. Chen, Chem. Commun. 2013, 49, 10938-10940. 
[7] F. Xiong, S. X. Huang, N. Gu, Drug Dev. Ind. Pharm. 2018, 44, 697-706. 
[8] C. T. Yu, M. J. Zhou, X. J. Zhang, W. J. Wei, X. F. Chen, X. H. Zhang, Nanoscale 2015, 
7, 5683-5690. 
[9] C. Y. Zhao, L. H. Shao, J. Q. Lu, X. W. Deng, Y. J. Tong, Y. Wu, ACS Appl. Mater. 
Interfaces 2017, 9, 18450-18461. 
[10] X. X. Dai, K. Han, Z. Y. Ma, H. Y. Han, Adv. Funct. Mater. 2018, 28, 1804609. 
[11] Q. W. Zhu, X. J. Chen, X. Xu, Y. Zhang, C. Zhang, R. Mo, Adv. Funct. Mater. 2018, 
28, 1707371. 
[12] J. Kolosnjaj-Tabi, R. Di Corato, L. Lartigue, I. Marangon, P. Guardia, A. K. A. Silva, 
N. Luciani, O. Clement, P. Flaud, J. V. Singh, P. Decuzzi, T. Pellegrino, C. Wilhelm, F. Gazeau, 
ACS Nano 2014, 8, 4268-4283. 
[13] L. Zhang, H. T. Su, Y. J. Liu, N. Pang, J. Li, X. R. Qi, J. Controlled Release 2019, 294, 
1-16. 
[14] A. R. Kirtane, T. Sadhukha, H. Kim, V. Khanna, B. Koniar, J. Panyam, Cancer Res. 




[15] D. L. Stirland, J. W. Nichols, E. Jarboe, M. Adelman, M. Dassel, M. M. Janat-Amsbury, 
Y. H. Bae, J. Controlled Release 2015, 214, 85-93. 
[16] C. H. Heldin, K. Rubin, K. Pietras, A. Ostman, Nat. Rev. Cancer 2004, 4, 806-813. 
[17] T. D. Tailor, G. Hanna, P. S. Yarmolenko, M. R. Dreher, A. S. Betof, A. B. Nixon, I. 
Spasojevic, M. W. Dewhirst, Mol. Cancer Ther. 2010, 9, 1798-1808. 
[18] A. A. Manzoor, L. H. Lindner, C. D. Landon, J. Y. Park, A. J. Simnick, M. R. Dreher, 
S. Das, G. Hanna, W. Park, A. Chilkoti, G. A. Koning, T. L. M. ten Hagen, D. Needham, M. 
W. Dewhirst, Cancer Res. 2012, 72, 5566-5575. 
[19] M. Longmire, P. L. Choyke, H. Kobayashi, Nanomedicine 2008, 3, 703-717. 
[20] K. Xiao, Y. P. Li, J. T. Luo, J. S. Lee, W. W. Xiao, A. M. Gonik, R. G. Agarwal, K. S. 
Lam, Biomaterials 2011, 32, 3435-3446. 
[21] W. Li, R. C. Luo, X. D. Lin, A. D. Jadhav, Z. C. Zhang, L. Yan, C. Y. Chan, X. F. Chen, 
J. F. He, C. H. Chen, P. Shi, Biomaterials 2015, 65, 76-85. 
[22] X. Y. Nan, X. J. Zhang, Y. Q. Liu, M. J. Zhou, X. F. Chen, X. H. Zhang, ACS Appl. 
Mater. Interfaces 2017, 9, 9986-9995. 
[23] A. Senyei, K. Widder, G. Czerlinski, J. Appl. Phys. 1978, 49, 3578-3583. 
[24] R. K. Jain, T. Stylianopoulos, Nat. Rev. Clin. Oncol. 2010, 7, 653-664. 
[25] L. Adamiak, M. A. Touve, C. L. M. LeGuyader, N. C. Gianneschi, ACS Nano 2017, 11, 
9877-9888. 
[26] Y. J. Liu, Z. T. Wang, Y. Liu, G. Z. Zhu, O. Jacobson, X. Fu, R. L. Bai, X. Y. Lin, N. 
Lu, X. Y. Yang, W. P. Fan, J. B. Song, Z. Wang, G. C. Yu, F. W. Zhang, H. Kalish, G. Niu, Z. 
H. Nie, X. Y. Chen, ACS Nano 2017, 11, 10539-10548. 
[27] G. Prencipe, S. M. Tabakman, K. Welsher, Z. Liu, A. P. Goodwin, L. Zhang, J. Henry, 
H. J. Dai, J. Am. Chem. Soc. 2009, 131, 4783-4787. 
[28] Z. Liu, C. Davis, W. B. Cai, L. He, X. Y. Chen, H. J. Dai, Proc. Natl. Acad. Sci. U. S. 




[29] S. Mura, J. Nicolas, P. Couvreur, Nat. Mater. 2013, 12, 991-1003. 
[30] H. Hashizume, P. Baluk, S. Morikawa, J. W. McLean, G. Thurston, S. Roberge, R. K. 
Jain, D. M. McDonald, Am. J. Pathol 2000, 156, 1363-1380. 
[31] F. Yuan, M. Dellian, D. Fukumura, M. Leunig, D. A. Berk, V. P. Torchilin, R. K. Jain, 
Cancer Res. 1995, 55, 3752-3756. 
[32] J. W. Nichols, Y. H. Bae, J. Controlled Release 2014, 190, 451-464. 
[33] F. Danhier, J. Controlled Release 2016, 244, 108-121. 
[34] A. Z. Wang, Sci. Transl. Med. 2015, 7, 294ec112-294ec112. 
[35] D. D. Lasic, Nature 1996, 380, 561-562. 
[36] F. M. Muggia, J. D. Hainsworth, S. Jeffers, P. Miller, S. Groshen, M. Tan, L. Roman, 
B. Uziely, L. Muderspach, A. Garcia, A. Burnett, F. A. Greco, C. P. Morrow, L. J. Paradiso, L. 
J. Liang, J. Clin. Oncol.  1997, 15, 987-993. 
[37] G. Batist, G. Ramakrishnan, C. S. Rao, A. Chandrasekharan, J. Gutheil, T. Guthrie, P. 
Shah, A. Khojasteh, M. K. Nair, K. Hoelzer, K. Tkaczuk, Y. C. Park, L. W. Lee, G. Myocet 
Study, J. Clin. Oncol.  2001, 19, 1444-1454. 
[38] J. Cortes, C. Saura, EJC Suppl. 2010, 8, 1-10. 
[39] V. J. I. p. Kumar Khanna, ISRN Pharmacol. 2012, 2012, 571394. 
[40] Z. L. Cheng, A. Al Zaki, J. Z. Hui, V. R. Muzykantov, A. Tsourkas, Science 2012, 338, 
903-910. 
[41] N. Nosrati, R. Abbasi, J. Charmi, A. Rakhshbahar, F. Aliakbarzadeh, H. Danafar, S. 
Davaran, Int. J. Biol. Macromol. 2018, 117, 1125-1132. 
[42] A. Beck, L. Goetsch, C. Dumontet, N. Corvaia, Nat. Rev. Drug Discovery 2017, 16, 
315-337. 
[43] C. Mamot, R. Ritschard, A. Wicki, G. Stehle, T. Dieterle, L. Bubendorf, C. Hilker, S. 




[44] P. A. Ott, R. D. Carvajal, N. Pandit-Taskar, A. A. Jungbluth, E. W. Hoffman, B. W. Wu, 
J. S. Bomalaski, R. Venhaus, L. D. Pan, L. J. Old, A. C. Pavlick, J. D. Wolchok, Invest. New 
Drugs 2013, 31, 425-434. 
[45] Q. X. Sun, T. Ojha, F. Kiessling, T. Lammers, Y. Shi, Biomacromolecules 2017, 18, 
1449-1459. 
[46] Q. Chen, L. Z. Feng, J. J. Liu, W. W. Zhu, Z. L. Dong, Y. F. Wu, Z. Liu, Adv. Mater 
2016, 28, 7129-7136. 
[47] B. Zhang, Y. Hu, Z. Q. Pang, Front. Pharmacol.  2017, 8, 952. 
[48] Z. W. Zhang, H. Wang, T. Tan, J. Li, Z. W. Wang, Y. P. Li, Adv. Funct. Mater.  2018, 
28, 1801840. 
[49] A. Orimo, R. A. Weinberg, Cell Cycle 2006, 5, 1597-1601. 
[50] L. E. Roode, H. Brighton, T. Bo, J. L. Perry, M. C. Parrott, F. Kersey, J. C. Luft, J. E. 
Bear, J. M. DeSimone, I. J. Davis, Nanomedicine 2016, 12, 1053-1062. 
[51] R. V. Iozzo, J. J. Zoeller, A. Nystrom, Mol. Cells 2009, 27, 503-513. 
[52] T. Shen, S. L. Guan, Z. H. Gan, G. Zhang, Q. S. Yu, Biomacromolecules 2016, 17, 1801-
1810. 
[53] H. Suzuki, Y. H. Bae, Biomaterials 2016, 98, 120-130. 
[54] F. Chen, K. Ma, B. Madajewski, L. Zhuang, L. Zhang, K. Rickert, M. Marelli, B. Yoo, 
M. Z. Turker, M. Overholtzer, T. P. Quinn, M. Gonen, P. Zanzonico, A. Tuesca, M. A. Bowen, 
L. Norton, J. A. Subramony, U. Wiesner, M. S. Bradbury, Nat. Commun. 2018, 9, 606-606. 
[55] F. Y. Liu, X. X. He, H. D. Chen, J. P. Zhang, H. M. Zhang, Z. X. Wang, Nat. Commun. 
2015, 6, 8003. 
[56] X. D. Zhang, Z. T. Luo, J. Chen, X. Shen, S. S. Song, Y. M. Sun, S. J. Fan, F. Y. Fan, 
D. T. Leong, J. P. Xie, Adv. Mater 2014, 26, 4565-4568. 




[58] Y. R. Zhang, R. Lin, H. J. Li, W. L. He, J. Z. Du, J. Wang, Wiley Interdiscip. Rev.: 
Nanomed. Nanobiotechnol. 2019, 11, e1519. 
[59] Y. Kato, S. Ozawa, C. Miyamoto, Y. Maehata, A. Suzuki, T. Maeda, Y. Baba, Cancer 
Cell Int. 2013, 13, 89. 
[60] P. Swietach, R. D. Vaughan-Jones, A. L. Harris, A. Hulikova, Philos. Trans. R. Soc., B 
2014, 369, 20130099. 
[61] L. L. Dai, K. Li, M. H. Li, X. J. Zhao, Z. Luo, L. Lu, Y. F. Luo, K. Y. Cai, Adv. Funct. 
Mater.  2018, 28, 1707249. 
[62] H. J. Li, J. Z. Du, J. Liu, X. J. Du, S. Shen, Y. H. Zhu, X. Y. Wang, X. D. Ye, S. M. Nie, 
J. Wang, ACS Nano 2016, 10, 6753-6761. 
[63] J. J. Chen, J. X. Ding, Y. C. Wang, J. J. Cheng, S. X. Ji, X. L. Zhuang, X. S. Chen, Adv. 
Mater 2017, 29, 1701170. 
[64] A. Jablonska-Trypuc, M. Matejczyk, S. Rosochacki, J. Enzyme Inhib. Med. Chem. 2016, 
31, 177-183. 
[65] Y. Liu, D. Zhang, Z. Y. Qiao, G. B. Qi, X. J. Liang, X. G. Chen, H. Wang, Adv. Mater 
2015, 27, 5034–5042. 
[66] H. Gerwien, S. Hermann, X. L. Zhang, E. Korpos, J. Song, K. Kopka, A. Faust, C. 
Wenning, C. C. Gross, L. Honold, N. Melzer, G. Opdenakker, H. Wiendl, M. Schafers, L. 
Sorokin, Sci. Transl. Med. 2016, 8, 364ra152. 
[67] Y. Q. Lv, C. R. Xu, X. M. Zhao, C. S. Lin, X. Yang, X. F. Xin, L. Zhang, C. Qn, X. P. 
Han, L. Yang, W. He, L. F. Yin, ACS Nano 2018, 12, 1519-1536. 
[68] C. Wong, T. Stylianopoulos, J. A. Cui, J. Martin, V. P. Chauhan, W. Jiang, Z. Popovic, 
R. K. Jain, M. G. Bawendi, D. Fukumura, Proc. Natl. Acad. Sci. U. S. A.  2011, 108, 2426-2431. 
[69] S. B. Ruan, X. Cao, X. L. Cun, G. L. Hu, Y. Zhou, Y. J. Zhang, L. B. Lu, Q. He, H. L. 




[70] Y. Hong, G. H. Nam, E. Koh, S. Jeon, G. B. Kim, C. Jeong, D. H. Kim, Y. Yang, I. S. 
Kim, Adv. Funct. Mater.  2018, 28, 1703074. 
[71] J. Wang, J. Liu, Y. Liu, L. M. Wang, M. J. Cao, Y. L. Ji, X. C. Wu, Y. Y. Xu, B. Bai, 
Q. Miao, C. Y. Chen, Y. L. Zhao, Adv. Mater 2016, 28, 8950-8958. 
[72] L. Hua, Z. Wang, L. Zhao, H. L. Mao, G. H. Wang, K. R. Zhang, X. J. Liu, D. M. Wu, 
Y. L. Zheng, J. Lu, R. T. Yu, H. M. Liu, Theranostics 2018, 8, 5088-5105. 
[73] A. Dirkse, A. Golebiewska, T. Buder, P. V. Nazarov, A. Muller, S. Poovathingal, N. H. 
Brons, S. Leite, N. Sauvageot, D. Sarkisjan, M. Seyfrid, S. Fritah, D. Stieber, A. Michelucci, F. 
Hertel, C. Herold-Mende, F. Azuaje, A. Skupin, R. Bjerkvig, A. Deutsch, A. Voss-Bohme, S. 
P. Niclou, Nat. Commun. 2019, 10, 1787. 
[74] B. Ma, H. C. Cheng, C. L. Mu, G. F. Geng, T. Zhao, Q. Luo, K. L. Ma, R. Chang, Q. Q. 
Liu, R. Z. Gao, J. L. Nie, J. Y. Xie, J. X. Han, L. B. Chen, G. Ma, Y. S. Zhu, Q. Chen, Nat. 
Commun. 2019, 10, 1034. 
[75] J. T. Xu, W. Han, P. P. Yang, T. Jia, S. M. Dong, H. T. Bi, A. Gulzar, D. Yang, S. L. 
Gai, F. He, J. Lin, C. X. Li, Adv. Funct. Mater.  2018, 28, 1803804. 
[76] J. Garcia-Bermudez, L. Baudrier, K. La, X. G. Zhu, J. Fidelin, V. O. Sviderskiy, T. 
Papagiannakopoulos, H. Molina, M. Snuderl, C. A. Lewis, R. L. Possemato, K. Birsoy, Nat. 
Cell Biol. 2018, 20, 775–781. 
[77] J. Wojton, Z. T. Chu, H. Mathsyaraja, W. H. Meisen, N. Denton, C. H. Kwon, L. M. L. 
Chow, M. Palascak, R. Franco, T. Bourdeau, S. Thornton, M. C. Ostrowski, B. Kaur, X. Y. Qi, 
Mol. Ther. 2013, 21, 1517-1525. 
[78] W. L. Wang, L. Lin, X. J. Ma, B. Wang, S. R. Liu, X. X. Yan, S. R. Li, H. Y. Tian, X. 
F. Yu, ACS Appl. Mater. Interfaces 2018, 10, 19398-19407. 
[79] D. Zhang, M. Wu, Z. X. Cai, N. S. Liao, K. Ke, H. Z. Liu, M. Li, G. Liu, H. H. Yang, 




[80] T. Thambi, V. G. Deepagan, H. Y. Yoon, H. S. Han, S. H. Kim, S. Son, D. G. Jo, C. H. 
Ahn, Y. D. Suh, K. Kim, I. C. Kwon, D. S. Lee, J. H. Park, Biomaterials 2014, 35, 1735-1743. 
[81] R. Tong, H. H. Chiang, D. S. Kohane, Proc. Natl. Acad. Sci. U. S. A.  2013, 110, 19048-
19053. 
[82] J. You, R. Zhang, C. Y. Xiong, M. Zhong, M. Melancon, S. Gupta, A. M. Nick, A. K. 
Sood, C. Li, Cancer Res. 2012, 72, 4777-4786. 
[83] X. L. Cun, M. Li, S. Y. Wang, Y. F. Wang, J. L. Wang, Z. Z. Lu, R. X. Yang, X. Tang, 
Z. R. Zhang, Q. He, Nanoscale 2018, 10, 9935-9948. 
[84] C. Hwang, A. J. Sinskey, H. F. Lodish, Science 1992, 257, 1496-1502. 
[85] Q. Zhang, C. N. Shen, N. Zhao, F. J. Xu, Adv. Funct. Mater. 2017, 27, 1606229. 
[86] X. Sun, J. Zhang, C. Yang, Z. Huang, M. Shi, S. Pan, H. Hu, M. Qiao, D. Chen, X. Zhao, 
ACS Appl. Mater. Interfaces 2019, 11, 11865-11875. 
[87] M. Y. Wu, Q. S. Meng, Y. Chen, L. X. Zhang, M. L. Li, X. J. Cai, Y. P. Li, P. C. Yu, L. 
L. Zhang, J. L. Shi, Adv. Mater 2016, 28, 1963–1969. 
[88] L. Hou, X. M. Yang, J. X. Ren, Y. C. Wang, H. J. Zhang, Q. H. Feng, Y. Y. Shi, X. N. 
Shan, Y. J. Yuan, Z. Z. Zhang, Int. J. Nanomed. 2016, 11, 607-624. 
[89] W. J. Wei, X. J. Zhang, X. F. Chen, M. J. Zhou, R. R. Xu, X. H. Zhang, Nanoscale 2016, 
8, 8118-8125. 
[90] F. Y. Zhou, B. Feng, T. T. Wang, D. G. Wang, Q. S. Meng, J. F. Zeng, Z. W. Zhang, S. 
L. Wang, H. J. Yu, Y. P. Li, Adv. Funct. Mater.  2017, 27, 1606530. 
[91] Y. F. Jiao, Y. F. Sun, B. S. Chang, D. R. Lu, W. L. Yang, Chem. - Eur. J. 2013, 19, 
15410-15420. 
[92] V. P. Chauhan, Z. Popovic, O. Chen, J. Cui, D. Fukumura, M. G. Bawendi, R. K. Jain, 
Angew. Chem., Int. Ed. 2011, 50, 11417-11420. 




[94] M. J. Zhou, X. J. Zhang, C. T. Yu, X. Y. Nan, X. F. Chen, X. H. Zhang, Nanomedicine 
2016, 12, 181-189. 
[95] B. D. Chithrani, A. A. Ghazani, W. C. W. Chan, Nano Lett. 2006, 6, 662-668. 
[96] Z. H. Wang, Y. H. Wang, X. Q. Jia, Q. J. Han, Y. X. Qian, Q. Li, J. F. Xiang, Q. Wang, 
Z. Y. Hu, W. Z. Wang, Theranostics 2019, 9, 1728-1740. 
[97] C. F. Song, T. T. Lin, Q. Zhang, S. Thayumanavan, L. Ren, J. Controlled Release 2019, 
293, 1-9. 
[98] S. Ohta, D. Glancy, W. C. W. Chan, Science 2016, 351, 841-845. 
[99] S. R. Saptarshi, A. Duschl, A. L. Lopata, J. Nanobiotechnol. 2013, 11, 26. 
[100] Q. G. Xu, L. M. Ensign, N. J. Boylan, A. Schon, X. Q. Gong, J. C. Yang, N. W. Lamb, 
S. T. Cai, T. Yu, E. Freire, J. Hanes, ACS Nano 2015, 9, 9217-9227. 
[101] J. S. Suk, Q. G. Xu, N. Kim, J. Hanes, L. M. Ensign, Adv. Drug Delivery Rev. 2016, 99, 
28-51. 
[102] E. A. Sykes, J. Chen, G. Zheng, W. C. W. Chan, ACS Nano 2014, 8, 5696-5706. 
[103] E. Ruoslahti, Adv. Drug Delivery Rev. 2017, 110, 3-12. 
[104] K. Cherukula, W. K. Bae, J. H. Lee, I. K. Park, Biomaterials 2018, 169, 45-60. 
[105] H. Y. Hu, J. Wang, H. Wang, T. Tang, J. Li, Z. W. Wang, K. X. Sun, Y. P. Li, Z. W. 
Zhang, Theranostics 2018, 8, 3597-3610. 
[106] L. Paasonen, S. Sharma, G. B. Braun, V. R. Kotamraju, T. D. Y. Chung, Z. G. She, K. 
N. Sugahara, M. Yliperttula, B. A. Wu, M. Pellecchia, E. Ruoslahti, T. Teesalu, Chembiochem 
2016, 17, 570-575. 
[107] E. J. Kwon, J. S. Dudani, S. N. Bhatia, Nat. Biomed. Eng. 2017, 1, 0054. 
[108] L. Zhang, Y. Wang, Y. T. Yang, Y. Y. Liu, S. B. Ruan, Q. Y. Zhang, X. W. Tai, J. T. 
Chen, T. Xia, Y. Qin, H. L. Gao, Q. He, ACS Appl. Mater. Interfaces 2015, 7, 9691-9701. 
[109] Y. P. Zhang, Y. Liu, X. F. Gao, X. M. Li, X. Y. Niu, Z. Yuan, W. Wang, Acta 




[110] X. Dong, H. J. Liu, H. Y. Feng, S. C. Yang, X. L. Liu, X. Lai, Q. Lu, J. F. Lovell, H. Z. 
Chen, C. Fang, Nano Lett. 2019, 19, 997-1008. 
[111] H. Gong, Y. Chao, J. Xiang, X. Han, G. S. Song, L. Z. Feng, J. J. Liu, G. B. Yang, Q. 
Chen, Z. Liu, Nano Lett. 2016, 16, 2512-2521. 
[112] X. X. Han, Y. Y. Li, Y. Xu, X. Zhao, Y. L. Zhang, X. Yang, Y. W. Wang, R. F. Zhao, 
G. J. Anderson, Y. L. Zhao, G. J. Nie, Nat. Commun. 2018, 9, 3390. 
[113] B. Zhang, T. Jiang, S. Shen, X. J. She, Y. Y. Tuo, Y. Hu, Z. Q. Pang, X. G. Jiang, 
Biomaterials 2016, 103, 12-21. 
[114] J. Zhang, J. S. Liu, Pharmacol. Ther. 2013, 137, 200-215. 
[115] N. Pang, J. Li, A. N. Sun, Z. Z. Yang, S. X. Cheng, X. R. Qi, Int. J. Nanomed. 2018, 13, 
5971-5990. 
[116] H. K. Erickson, P. U. Park, W. C. Widdison, Y. V. Kovtun, L. M. Garrett, K. Hoffman, 
R. J. Lutz, V. S. Goldmacher, W. A. Blattler, Cancer Res. 2006, 66, 4426-4433. 
[117] Y. Bao, H. H. Guo, Y. L. Lu, W. M. Feng, X. R. Sun, C. W. Tang, X. Wang, M. Shen, 
Oncotarget 2016, 7, 77183-77195. 
[118] D. D. Sun, Y. N. Liu, Q. Q. Yu, Y. H. Zhou, R. Zhang, X. J. Chen, A. Hong, J. Liu, 
Biomaterials 2013, 34, 171-180. 
[119] K. C. Valkenburg, A. E. de Groot, K. J. Pienta, Nat. Rev. Clin. Oncol. 2018, 15, 366-
381. 
[120] T. J. Ji, Y. P. Ding, Y. Zhao, J. Wang, H. Qin, X. M. Liu, J. Y. Lang, R. F. Zhao, Y. L. 
Zhang, J. Shi, N. Tao, Z. H. Qin, G. J. Nie, Adv. Mater 2015, 27, 1865-1873. 
[121] J. E. Park, M. C. Lenter, R. N. Zimmermann, P. Garin-Chesa, L. J. Old, W. J. Rettig, J. 
Biol. Chem. 1999, 274, 36505-36512. 
[122] L. Miao, Y. H. Wang, C. M. Lin, Y. Xiong, N. H. Chen, L. Zhang, W. Y. Kim, L. Huang, 




[123] S. Lee, H. Han, H. Koo, J. H. Na, H. Y. Yoon, K. E. Lee, H. Lee, H. Kim, I. C. Kwon, 
K. Kim, J. Controlled Release 2017, 263, 68-78. 
[124] V. P. Chauhan, T. Stylianopoulos, J. D. Martin, Z. Popovic, O. Chen, W. S. Kamoun, 
M. G. Bawendi, D. Fukumura, R. K. Jain, Nat. Nanotechnol.  2012, 7, 383-388. 
[125] M. A. Iniguez, A. Rodriguez, O. V. Volpert, M. Fresno, J. M. Redondo, Trends Mol. 
Med. 2003, 9, 73-78. 
[126] H. S. Kim, A. Sharma, W. X. Ren, J. Y. Han, J. S. Kim, Biomaterials 2018, 185, 63-72. 
[127] B. Zhang, K. Jin, T. Jiang, L. T. Wang, S. Shen, Z. M. Luo, Y. Y. Tuo, X. P. Liu, Y. 
Hu, Z. Q. Pang, Sci. Rep. 2017, 7, 10071. 
[128] C. Y. Lin, H. C. Tseng, H. R. Shiu, M. F. Wu, C. Y. Chou, W. L. Lin, Int. J. Nanomed. 
2012, 7, 2143-2152. 
[129] P. Diagaradjane, A. Shetty, J. C. Wang, A. M. Elliott, J. Schwartz, S. Shentu, H. C. Park, 
A. Deorukhkar, R. J. Stafford, S. H. Cho, J. W. Tunnell, J. D. Hazle, S. Krishnan, Nano Lett. 
2008, 8, 1492-1500. 
[130] S. Kunjachan, A. Detappe, R. Kumar, T. Ireland, L. Cameron, D. E. Biancur, V. Motto-
Ros, L. Sancey, S. Sridhar, G. M. Makrigiorgos, R. I. Berbeco, Nano Lett. 2015, 15, 7488-7496. 
[131] A. B. Satterlee, J. D. Rojas, P. A. Dayton, L. Huang, Theranostics 2017, 7, 253-269. 
[132] B. Theek, M. Baues, T. Ojha, D. Mockel, S. K. Veettil, J. Steitz, L. van Bloois, G. Storm, 
F. Kiessling, T. Lammers, J. Controlled Release 2016, 231, 77-85. 
[133] R. J. Akhurst, A. Hata, Nat. Rev. Drug Discovery 2012, 11, 790-811. 
[134] C. Margadant, A. Sonnenberg, EMBO Rep. 2010, 11, 97-105. 
[135] H. Cabral, Y. Matsumoto, K. Mizuno, Q. Chen, M. Murakami, M. Kimura, Y. Terada, 
M. R. Kano, K. Miyazono, M. Uesaka, N. Nishiyama, K. Kataoka, Nat. Nanotechnol.  2011, 6, 
815-823. 
[136] G. Yang, S. Z. F. Phua, W. Q. Lim, R. Zhang, L. Feng, G. Liu, H. Wu, A. K. Bindra, D. 




[137] F. Gong, L. Cheng, N. Yang, O. Betzer, L. Feng, Q. Zhou, Y. Li, R. Chen, R. Popovtzer, 
Z. Liu, Adv. Mater 2019, 31, 1900730. 
[138] Q. Chen, L. G. Xu, J. W. Chen, Z. J. Yang, C. Liang, Y. Yang, Z. Liu, Biomaterials 
2017, 148, 69-80. 
[139] P. Vaupel, L. Harrison, Oncologist 2004, 9, 4-9. 
[140] D. L. Xia, P. P. Xu, X. Y. Luo, J. F. Zhu, H. Y. Gu, D. Huo, Y. Hu, Adv. Funct. Mater.  
2019, 29, 1807294. 
[141] X. J. Song, L. Z. Feng, C. Liang, M. Gao, G. S. Song, Z. Liu, Nano Research 2017, 10, 
1200-1212. 
[142] M. Benej, X. Q. Hong, S. Vibhute, S. Scott, J. H. Wu, E. Graves, Q. T. Le, A. C. Koong, 
A. J. Giaccia, B. Yu, S. C. Chen, I. Papandreou, N. C. Denko, Proc. Natl. Acad. Sci. U. S. A. 
2018, 115, 10756-10761. 
[143] E. Milotti, S. Stella, R. Chignola, Sci. Rep. 2017, 7, 39762. 
[144] J. F. Lin, J. Li, A. Gopal, T. Munshi, Y. W. Chu, J. X. Wang, T. T. Liu, B. Y. Shi, X. F. 
Chen, L. Yan, Chem. Commun. 2019, 55, 2656-2659. 
[145] L. Yan, Z. G. Wang, X. F. Chen, X. J. Gou, Z. Y. Zhang, X. Y. Zhu, M. H. Lan, W. 
Chen, G. Y. Zhu, W. J. Zhang, Chem. Commun. 2017, 53, 2339-2342. 
[146] D. Min, D. Jeong, M. G. Choi, K. Na, Biomaterials 2015, 52, 484-493. 
[147] C. G. Qian, J. C. Yu, Y. L. Chen, Q. Y. Hu, X. Z. Xiao, W. J. Sun, C. Wang, P. J. Feng, 
Q. D. Shen, Z. Gu, Adv. Mater 2016, 28, 3313-3320. 
[148] X. L. Huang, J. Chisholm, J. Zhuang, Y. Y. Xiao, G. Duncan, X. Y. Chen, J. S. Suk, J. 
Hanes, Proc. Natl. Acad. Sci. U. S. A. 2017, 114, E6595-E6602. 
[149] X. L. Huang, J. Zhuang, S. W. Chung, B. W. Huang, G. Halpert, K. Negron, X. R. Sun, 
J. Yang, Y. Oh, P. M. Hwang, J. Hanes, J. S. Suk, ACS Nano 2019, 13, 236-247. 




[151] T. Y. Wang, K. E. Wilson, S. Machtaler, J. K. Willmann, Curr. Pharm. Biotechnol. 
2013, 14, 743-752. 
[152] A. M. Malekzadeh, A. Ramazani, S. J. T. Rezaei, H. Niknejad, J. Colloid Interface Sci. 
2017, 490, 64-73. 
[153] A. Nacev, A. Komaee, A. Sarwar, R. Probst, S. H. Kim, M. Emmert-Buck, B. Shapiro, 
IEEE Control Syst. Mag. 2012, 32, 32-74. 
[154] A. S. Lubbe, C. Bergemann, H. Riess, F. Schriever, P. Reichardt, K. Possinger, M. 
Matthias, B. Dorken, F. Herrmann, R. Gurtler, P. Hohenberger, N. Haas, R. Sohr, B. Sander, 
A. J. Lemke, D. Ohlendorf, W. Huhnt, D. Huhn, Cancer Res. 1996, 56, 4686-4693. 
[155] O. Felfoul, M. Mohammadi, S. Taherkhani, D. de Lanauze, Y. Z. Xu, D. Loghin, S. 
Essa, S. Jancik, D. Houle, M. Lafleur, L. Gaboury, M. Tabrizian, N. Kaou, M. Atkin, T. Vuong, 
G. Batist, N. Beauchemin, D. Radzioch, S. Martel, Nat. Nanotechnol.  2016, 11, 941-947. 
[156] X. M. Guo, Z. Wu, W. Li, Z. H. Wang, Q. P. Li, F. F. Kong, H. B. Zhang, X. L. Zhu, Y. 
P. P. Du, Y. Jin, Y. Z. Du, J. You, ACS Appl. Mater. Interfaces 2016, 8, 3092-3106. 
[157] M. Shamsi, A. Sedaghatkish, M. Dejam, M. Saghafian, M. Mohammadi, A. Sanati-
Nezhad, Drug Delivery 2018, 25, 846-861. 
[158] M. Muthana, A. J. Kennerley, R. Hughes, E. Fagnano, J. Richardson, M. Paul, C. 
Murdoch, F. Wright, C. Payne, M. F. Lythgoe, N. Farrow, J. Dobson, J. Conner, J. M. Wild, C. 
Lewis, Nat. Commun. 2015, 6, 8009. 
[159] S. Schuerle, A. P. Soleimany, T. Yeh, G. M. Anand, M. Häberli, H. E. Fleming, N. 
Mirkhani, F. Qiu, S. Hauert, X. Wang, B. J. Nelson, S. N. Bhatia, Sci. Adv. 2019, 5, eaav4803. 
[160] P. Lam, R. D. Lin, N. F. Steinmetz, J. Mater. Chem. B 2018, 6, 5888-5895. 
[161] T. D. McKee, P. Grandi, W. Mok, G. Alexandrakis, N. Insin, J. P. Zimmer, M. G. 
Bawendi, Y. Boucher, X. O. Breakefield, R. K. Jain, Cancer Res. 2006, 66, 2509-2513. 
[162] A. E. Smith, A. Helenius, Science 2004, 304, 237-242. 




[164] S. Kilcher, J. Mercer, Virology 2015, 479, 578-590. 
[165] B. Huang, D. J. Irvine, Cancer Res. 2011, 71, 4432-4432. 
[166] M. Bernardes-Silva, D. C. Anthony, A. C. Issekutz, V. H. Perry, J. Cereb. Blood Flow 
Metab. 2001, 21, 1115-1124. 
[167] J. W. Xue, Z. K. Zhao, L. Zhang, L. J. Xue, S. Y. Shen, Y. J. Wen, Z. Y. Wei, L. Wang, 
L. Y. Kong, H. B. Sun, Q. N. Ping, R. Mo, C. Zhang, Nat. Nanotechnol.  2017, 12, 692-700. 
[168] X. Zhang, X. H. Xu, Y. C. Li, C. Hu, Z. J. Zhang, Z. W. Gu, Adv. Mater 2018, 30, 
1707240. 
[169] Y. Takechi-Haraya, Y. Goda, K. Sakai-Kato, Mol. Pharmaceutics 2017, 14, 2158-2165. 
[170] L. Zhang, P. Y. Hao, D. J. Yang, S. Feng, B. Peng, D. Appelhans, T. H. Zhang, X. J. 
Zan, J. Mater. Chem. B 2019, 7, 953-964. 
[171] F. Peng, M. I. Setyawati, J. K. Tee, X. G. Ding, J. P. Wang, M. E. Nga, H. K. Ho, D. T. 
Leong, Nat. Nanotechnol. 2019, 14, 279–286. 
[172] X. F. Chen, Adv. Drug Delivery Rew. 2018, 127, 85-105. 
[173] N. N. Zhao, L. M. Yan, X. Y. Zhao, X. Y. Chen, A. H. Li, D. Zheng, X. Zhou, X. G. 
Dai, F. J. Xu, Chem. Rev. 2019, 119, 1666-1762. 
[174] R. R. Wang, Y. Hu, N. N. Zhao, F. J. Xu, ACS Appl. Mater. Interfaces 2016, 8, 11298-
11308. 
[175] S. Duan, Y. J. Yang, C. L. Zhang, N. N. Zhao, F. J. Xu, Small 2017, 13,1603133. 
[176] Y. X. Qian, Y. H. Wang, F. Jia, Z. H. Wang, C. Y. Yue, W. K. Zhang, Z. Y. Hu, W. Z. 
Wang, Biomaterials 2019, 188, 96-106. 
[177] T. T. Wang, D. G. Wang, J. P. Liu, B. Feng, F. Y. Zhou, H. W. Zhang, L. Zhou, Q. Yin, 
Z. W. Zhang, Z. L. Cao, H. J. Yu, Y. P. Li, Nano Lett. 2017, 17, 5429-5436. 
[178] R. Agarwal, P. Jurney, M. Raythatha, V. Singh, S. V. Sreenivasan, L. Shi, K. Roy, Adv. 




[179] K. P. Valente, S. S. Thind, M. Akbari, A. Suleman, A. G. Brolo, ACS Biomater. Sci. 
Eng. 2019, 5, 2887-2898. 
[180] A. Albanese, A. K. Lam, E. A. Sykes, J. V. Rocheleau, W. C. W. Chan, Nat. Commun. 
2013, 4, 2718. 
[181] A. Tchoryk, V. Taresco, R. H. Argent, M. Ashford, P. R. Gellert, S. Stolnik, A. 
Grabowska, M. C. Garnett, Bioconjugate Chem. 2019, 30, 1371-1384. 
[182] J. Friedrich, C. Seidel, R. Ebner, L. A. Kunz-Schughart, Nat. Protoc. 2009, 4, 309-324. 
[183] M. R. DeWitt, M. N. Rylander, in Targeted Drug Delivery: Methods and Protocols, Vol. 
1831 (Eds: R. W. Sirianni, B. Behkam), 2018, pp. 159-178. 
[184] N. E. Clay, K. Shin, A. Ozcelildalei, M. K. Lee, M. H. Rich, D. H. Kim, B. Han, H. 
Kong, ACS Biomater. Sci. Eng. 2016, 2, 1968-1975. 
[185] H. Jin, T. Zhu, X. G. Huang, M. Sun, H. G. Li, X. Y. Zhu, M. L. Liu, Y. B. Xie, W. 
Huang, D. Y. Yan, Biomaterials 2019, 211, 68-80. 
[186] C. Wang, S. Q. Chen, Y. X. Wang, X. R. Liu, F. Q. Hu, J. H. Sun, H. Yuan, Adv. Mater 
2018, 30, 1706407. 
[187] C. Y. Ju, R. Mo, J. W. Xue, L. Zhang, Z. K. Zhao, L. J. Xue, Q. N. Ping, C. Zhang, 
Angew. Chem., Int. Ed. 2014, 53, 6253-6258. 
[188] C. Denkert, S. Loibl, A. Noske, M. Roller, B. M. Muller, M. Komor, J. Budczies, S. 
Darb-Esfahani, R. Kronenwett, C. Hanusch, C. von Torne, W. Weichert, K. Engels, C. Solbach, 
I. Schrader, M. Dietel, G. von Minckwitz, J. Clin. Oncol.  2010, 28, 105-113. 
[189] D. V. Krysko, A. D. Garg, A. Kaczmarek, O. Krysko, P. Agostinis, P. Vandenabeele, 
Nat. Rev. Cancer 2012, 12, 860-875. 
[190] K. E. de Visser, A. Eichten, L. M. Coussens, Nat. Rev. Cancer 2006, 6, 24-37. 
[191] S. I. Grivennikov, F. R. Greten, M. Karin, Cell 2010, 140, 883-899. 




[193] M. P. Vadevoo, S. Gurung, F. Khan, M. E. Haque, G. R. Gunassekaran, L. H. Chi, U. 
Permpoon, B. Lee, Arch. Pharmacal Res. 2019, 42, 150-158. 
[194] Y. Z. Chen, W. T. Song, L. M. Shen, N. S. Qiu, M. Y. Hu, Y. Liu, Q. Liu, L. Huang, 
ACS Nano 2019, 13, 1751-1763. 
[195] X. W. Guan, L. Lin, J. Chen, Y. Y. Hu, P. J. Sun, H. Y. Tian, A. Maruyama, X. S. Chen, 
J. Controlled Release 2019, 293, 104-112. 
[196] M. E. Davis, Mol. Pharmaceutics 2009, 6, 659-668. 
[197] A. Wicki, D. Witzigmann, V. Balasubramanian, J. Huwyler, J. Controlled Release 2015, 
200, 138-157. 
[198] Y. X. Tang, Y. H. Li, S. Li, H. Hu, Y. X. Wu, C. Xiao, Z. Q. Chu, Z. F. Li, X. L. Yang, 
Nanoscale 2019, 11, 6217-6227. 
[199] H. J. Li, J. Z. Du, X. J. Du, C. F. Xu, C. Y. Sun, H. X. Wang, Z. T. Cao, X. Z. Yang, Y. 
H. Zhu, S. M. Nie, J. Wang, Proc. Natl. Acad. Sci. U. S. A. 2016, 113, 4164-4169. 
[200] Z. Popovic, W. H. Liu, V. P. Chauhan, J. Lee, C. Wong, A. B. Greytak, N. Insin, D. G. 
Nocera, D. Fukumura, R. K. Jain, M. G. Bawendi, Angew. Chem., Int. Ed. 2010, 49, 8649-8652. 
[201] E. A. Nance, G. F. Woodworth, K. A. Sailor, T. Y. Shih, Q. G. Xu, G. Swaminathan, D. 
Xiang, C. Eberhart, J. Hanes, Sci. Transl. Med. 2012, 4, 149ra119. 
[202] H. Lee, H. Fonge, B. Hoang, R. M. Reilly, C. Allen, Mol. Pharmaceutics 2010, 7, 1195-
1208. 
[203] T. Wei, J. Liu, H. L. Ma, Q. Cheng, Y. Y. Huang, J. Zhao, S. D. Huo, X. D. Xue, Z. C. 
Liang, X. J. Liang, Nano Lett. 2013, 13, 2528-2534. 
[204] R. M. Davis, B. Kiss, D. R. Trivedi, T. J. Metzner, J. C. Liao, S. S. Gambhir, ACS Nano 
2018, 12, 9669-9679. 
[205] Y. Cong, L. Ji, Y. J. Gao, F. H. Liu, D. B. Cheng, Z. Y. Hu, Z. Y. Qiao, H. Wang, Angew. 




[206] L. Li, T. L. M. ten Hagen, M. Bolkestein, A. Gasselhuber, J. Yatvin, G. C. van Rhoon, 
A. M. M. Eggermont, D. Haemmerich, G. A. Koning, J. Controlled Release 2013, 167, 130-
137. 
[207] C. Carlier, B. Laforce, S. J. M. Van Malderen, F. Gremonprez, R. Tucoulou, J. Villanova, 
O. De Wever, L. Vincze, F. Vanhaecke, W. Ceelen, J. Pharm. Biomed. Anal. 2016, 131, 256-
262. 
[208] W. C. Huang, W. H. Chiang, Y. H. Cheng, W. C. Lin, C. F. Yu, C. Y. Yen, C. K. Yeh, 
C. S. Chern, C. S. Chiang, H. C. Chiu, Biomaterials 2015, 71, 71-83. 
[209] Q. Zhou, S. Shao, J. Wang, C. Xu, J. Xiang, Y. Piao, Z. Zhou, Q. Yu, J. Tang, X. Liu, 
Z. Gan, R. Mo, Z. Gu, Y. Shen, Nat. Nanotechnol. 2019, 10, 1038. 
[210] G. Kroemer, L. Galluzzi, O. Kepp, L. Zitvogel, in Annual Review of Immunology, Vol. 
31 (Eds: D. R. Littman, W. M. Yokoyama), 2013, pp. 51-72. 
[211] X. D. Xue, Y. Huang, R. N. Bo, B. Jia, H. Wu, Y. Yuan, Z. L. Wang, Z. Ma, D. Jing, X. 
B. Xu, W. M. Yu, T. Y. Lin, Y. P. Li, Nat. Commun. 2018, 9, 3653. 
[212] S. Tang, Q. S. Meng, H. P. Sun, J. H. Su, Q. Yin, Z. W. Zhang, H. J. Yu, L. L. Chen, 
W. W. Gu, Y. P. Li, Biomaterials 2017, 114, 44-53. 
[213] C. Hu, X. L. Cun, S. B. Ruan, R. Liu, W. Xiao, X. T. Yang, Y. Y. Yang, C. Y. Yang, H. 
L. Gao, Biomaterials 2018, 168, 64-75. 
[214] S. Khatoon, H. S. Han, J. Jeon, N. V. Rao, D. W. Jeong, M. Ikram, T. Yasin, G. R. Yi, 
J. H. Park, Polymers 2018, 10, 390. 
[215] Z. B. Li, M. Wu, H. Z. Bai, X. G. Liu, G. P. Tang, Chem. Commun. 2018, 54, 13127-
13130. 
[216] W. D. Ke, W. Yin, Z. S. Zha, J. F. Mukerabigwi, W. J. Chen, Y. H. Wang, C. X. He, Z. 
S. Ge, Biomaterials 2018, 154, 261-274. 
[217] P. H. Zhang, Y. Wang, J. Lian, Q. Shen, C. Wang, B. H. Ma, Y. C. Zhang, T. T. Xu, J. 




[218] Z. R. Wang, Q. He, W. G. Zhao, J. W. Luo, W. P. Gao, J. Controlled Release 2017, 264, 
66-75. 
[219] T. Y. Yong, J. Hu, X. Q. Zhang, F. Y. Li, H. Yang, L. Gan, X. L. Yang, ACS Appl. 
Mater. Interfaces 2016, 8, 27611-27621. 
[220] Y. J. Zhang, W. Z. Chen, C. C. Yang, Q. L. Fan, W. Wu, X. Q. Jiang, J. Controlled 
Release 2016, 237, 115-124. 
[221] C. Hu, X. T. Yang, R. Liu, S. B. Ruan, Y. Zhou, W. Xiao, W. Q. Yu, C. Y. Yang, H. L. 
Gao, ACS Appl. Mater. Interfaces 2018, 10, 22571-22579. 
[222] Y. Jiang, X. Pang, R. L. Liu, Q. C. Xiao, P. Wang, A. W. Leung, Y. X. Luan, C. S. Xu, 
ACS Appl. Mater. Interfaces 2018, 10, 31674-31685. 
[223] J. E. Zhou, J. Yu, L. P. Gao, L. Sun, T. Peng, J. Wang, J. Z. Zhu, W. Y. Lu, L. Zhang, 
Z. Q. Yan, L. Yu, Mol. Pharmaceutics 2017, 14, 1811-1820. 
[224] Y. Q. Zhu, Z. Jian, F. H. Meng, D. Chao, C. Ru, J. Feijen, Z. Y. Zhong, ACS Appl. Mater. 
Interfaces 2017, 9, 35651-35663. 
[225] R. Loria, C. Giliberti, A. Bedini, R. Palomba, G. Caracciolo, P. Ceci, E. Falvo, R. 
Marconi, R. Falcioni, G. Bossi, L. Strigari, J. Exp. Clin. Cancer Res. 2019, 38, 11. 
[226] W. Feng, R. Wang, Y. Zhou, L. Ding, X. Gao, B. Zhou, P. Hu, Y. Chen, Adv. Funct. 
Mater.  2019, 29, 1901942. 
[227] J. Kolosnjaj-Tabi, I. Marangon, A. Nicolas-Boluda, A. K. A. Silva, F. Gazeau, 
Pharmacol. Res. 2017, 126, 123-137. 
[228] L. Beola, L. Asin, R. M. Fratila, V. Herrero, J. M. de la Fuente, V. Grazu, L. Gutierrez, 
ACS Appl. Mater. Interfaces 2018, 10, 44301-44313. 
[229] N. Schleich, C. Po, D. Jacobs, B. Ucakar, B. Gallez, F. Danhier, V. Preat, J. Controlled 
Release 2014, 194, 82-91. 
[230] M. Wang, J. J. Li, X. J. Li, H. J. Mu, X. M. Zhang, Y. N. Shi, Y. C. Chu, A. P. Wang, 




[231] Q. X. Ma, L. Cheng, F. Gong, Z. L. Dong, C. Liang, M. Y. Wang, L. Z. Feng, Y. G. Li, 
Z. Liu, C. Li, L. He, J. Mater. Chem. B 2018, 6, 5069-5079. 
[232] G. B. Yang, L. G. Xu, Y. Chao, J. Xu, X. Q. Sun, Y. F. Wu, R. Peng, Z. Liu, Nat. 
Commun. 2017, 8, 902. 
[233] L. Zhang, H. J. Yi, J. Song, J. Huang, K. Yang, B. Tan, D. Wang, N. L. Yang, Z. G. 














matrix Stromal cells Elevated interstitial fluid pressure 
Barriers 











































Figure 2. The three transport steps of nanomedicines targeting delivery; Passive targeting (EPR 
effect) through drug accumulation in leaky vasculature areas. There are no ruptures in the 
normal tissue, therefore, the drug is transported through the blood vessel steadily. The drug 
percolates through holes in the tumor-affected region and accumulates within the tumor; The 
barriers to deep penetration of NPs inflicted by the tumor microenvironment, including IFP, 







Figure 3. Physico-chemical characterization of a drug. Reproduced with permission.[197] 
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Figure 5. (A) Tumor-pH-triggered size transition of SCNs/Pt. (a) DLS (left panel) and TEM 
(right panel) measurements of SCNs/Pt in phosphate buffer (PB) at pH 7.4. (b) pH-Dependent 
size change of SCNs/Pt analyzed by DLS. (c) DLS (left panel) and TEM (right panel) 
measurements of SCNs/Pt at pH 6.7. (d) Gel filtration chromatography analysis of SCNs/Pt 
treated at pH 6.7 and 7.4. (B) Self‐Assembly and sequential stimuli‐responsibilities of SNP. 
(a,d) Morphologies of a) NP and d) SNP in PBS at pH 7.4 or 6.8 without or with 10.0 mM 
glutathione (GSH) detected by TEM. (b,e) Changes of zeta potentials of b) NP and e) SNP in 
PBS at pH 7.4 or 6.8. (c,f) DOX release behaviors of c) NP and f) SNP in PBS at pH 7.4 or 6.8 
without or with 10.0 mM GSH. Reproduced with permission.[62-63] Copyright 2016, ACS Nano. 







Figure 6. In vitro multicellular tumor spheroid penetration of DGL/DOX@PP, DGL/DOX-PP 
+ MMP-2 1 h (pretreated with 300 ng mL−1 MMP-2 for 1 h) and DGL/DOX@PP + MMP-2 1 
h (pretreated with 300 ng mL−1 MMP-2 for 1 h) after 24 h of incubation in different depths. The 
concentration of DOX used was 10 μg mL−1. Green represents DOX. Bar represents 200 μm. 






Figure 7. Schematic illustration of hierarchical disassembly of RPSPT@SNCs. A 
typical RPSPT@SNCs was composed of RGD-mediated, redox-responsive micelles loaded 
with PTX, which was incorporated into an extracellular matrix metalloproteinase-2-responsive 
cross-linked network. (a) Preparation procedure of RPSPT. (b) Preparation procedure 
of RPSPT@SNCs. (c) RPSPT@SNCs could accumulate into tumor tissue via an EPR effect. 
(d) RPSPT@SNCs could be degraded in the presence of high concentration of MMP-2 and 
release small-sized RPSPT to possess higher tumor penetration. (e) When RPSPT was 
accumulated into tumor tissue, it could be internalized into tumor cells via RGD-mediated cell 
endocytosis. In an acidic endo/lysosomal environment, PEI could possess a proton sponge 




presence of high concentration of GSH and eventually lead to intracellular drug accumulation 
to exert preferable antitumor activity. Reproduced with permission.[86] Copyright 2019, ACS 






Figure 8. Characterizations of HEKMs. (A) DLS and TEM images of HEKMs without MMP-
2. (B) DLS and TEM images of HEKMs incubated with MMP-2 for 2 h. (C) DLS and TEM 
images of HEKMs incubated with MMP-2 for 4 h. The scale bar indicates 200 nm. (D) 
Molecular simulation of the secondary structures of HEKMs before MMP-2 cleavage. (E) 
Molecular simulation of the secondary structures of HEKMs after cleavage. (F) Illustration of 
the preparation of PTX/MTAs from PDEA-b-P(OEGMA-co-PDS) copolymer and the pH-
sensitive morphological transition. Reproduced with permission.[96-97] Copyright 2019, 






Figure 9. (A) To change the shape of the nanoassembly, attaching strands (A1) were added to 
anchor small satellites to the medium particle. After that, the detaching strand (L1comp) was 
added to dislocate L1, resulting in the relocation of small satellites from the large core to the 
medium satellites (assembly morphology 2). This shape change can be reversed by adding extra 
attaching and detaching strands, L1 and A1comp. (B) Representative TEM images of the 
nanoassemblies of morphology 1, intermediate, and morphology 2. They consist of 13-, 6-, and 
3-nm gold NPs.The orange and red circles indicate a 13- and 6-nm particle, respectively. Scale 
bar, 20 nm. (C) In assembly morphology 1, FA is surrounded by satellite NPs, which impedes 
its targeting property (“OFF” state). Then after the shift to morphology 2, the “hidden” FA is 
exposed to the outer environment, which activates the cellular uptake property of the assemblies 






Figure 10. The effects of PEG surface density with mucus in vitro, ex vivo, and in vivo. Above 
a certain threshold (5% PEG), NPs were more stable in vitro, diffused rapidly ex vivo, and 
distributed more uniformly in vivo. Reproduced with permission.[101] Copyright 2016, 






Figure 11. Schematic Illustration about the effect of losartan and the pH sensitive liposomes (PTX-Cl-









Figure 12. Schematic graphs of the tumor microenvironment and nanotherapeutics delivery to 
tumors rich in vessels and ECM before and after celecoxib treatment. Before celecoxib 
treatment, the tumor vessels were leaky and compressed by tumor ECM and TAF, which were 
a main contributor to the heterogeneous perfusion in tumors and, accordingly, the compromised 
nanotherapeutics delivery to tumors. As a comparison, celecoxib treatment reduced TAF, 
disrupted tumor ECM, and repaired tumor vessels to enhance their maturity, which ultimately 
improved tumor perfusion and enhanced tumor nanotherapeutics delivery. Reproduced with 






Figure 13. (a) In vivo behaviors of PEG-FTn75%. Representative confocal images showing 
accumulation of systemically administered PEG-FTn75% (red) in hypoxic areas (green) within a 
3LL-based orthotopic lung tumor tissue. Magenta color represents blood vessels. Scale bar = 
100 μm. (b) Image-based quantification of PEG-FTn75% localization in normoxic and hypoxic 
tumor areas at different time points after the administration (n = 4). (c) Flow cytometry analysis 
of accumulation of PEG-FTn75%, in comparison to non-PEGylated FTn, in normoxic and 
hypoxic tumor areas 18 h after the administration. Reproduced with permission.[149] Copyright 





Figure 14. (A) Pathophysiology of tumors gives rise to opposing convective flows of the 
interstitial fluid at the tumor periphery which repel MNPs. Magnetic forces can be applied to 
counteract these effects. (B) Schematic of the proposed magnetically assisted Intraperitoneal 
chemotherapy. Horizontal disposition of the peritoneum targeted with drug-loaded magnetic 
NPs (MNPs). A permanent external magnet is utilized to impel MNPs across tumor nodules 
and surpass interstitial barriers. (C) MRT using a novel transendothelial migration (TEM) flow 
assay. A flow chamber that can accommodate 3D tumor spheroids as well as a vascular 
endothelial layer. (C, left panel). The TEM flow chamber is placed in the isocenter of an MRI 
scanner. The resulting heterogeneous magnetic field (dB/dy field) can steer magnetic particles 
towards the tumor spheroids for increased uptake (C, right panel). (D) Uptake was confirmed 
by a distortion in the MRI image and a loss of signal compared with when no MRT was applied 
(D, upper panel). Corresponding fluorescent images of whole spheroids infiltrated with 
macrophages carrying a reporter adenovirus (Ad-CMV-GFP) are shown in (D, second panel). 
Scale bar, 100 μm. Reproduced with permission.[157, 159] Copyright 2018, Drug Delivery. 







Figure 15. Specific fluorescence ‘switch on’ performance of STD-NM. Time-dependent 
fluorescence spectra of TPE in STD-NM after treatment with caspase-3 (A) and caspase-3 with 
its inhibitor (B). C) The fluorescence intensity ratios of TPE in (A) and (B). FI0: the 
fluorescence intensity at 0 h, FIt: the fluorescence intensity at different points in time. D) Real-
time CLSM images displaying the apoptotic progress of STD-NM stained HUVEC cells at pH 
6.5. Nuclei were live stained with DRAQ5 (yellow). All images share the same scale bar 







Figure 16. (A) Acid-triggered activation of fluorescence and photodynamic properties of 
iPAPD NPs (fluorescence imaging was performed at Ex = 640 nm and Em = 680 nm for Ce6). 
(B) Quantitative examination of DOX distribution in the tumor xenograft 2 or 24 h postinjection 
(*** p < 0.01). (C) In vivo antitumor performance of ATLP NPs. TUNEL staining of the tumor 
















Figure 17. The maximum penetration depth of nanomedicines in xenograft mice tumor models 
via intravenous injection in 21 publications.[17-18, 61, 63, 132, 135, 146, 185, 194, 198-209] The depth is 

















































Figure 18. Illustration of formation and elevated antitumor mechanism of “Pandora's box” 

















Figure 19. Properties of immunogenic cell death (ICD). As a result of premortem endoplasmic 
reticulum stress and autophagy, cancer cells responding to ICD inducers expose CRT on the 
outer leaflet of their plasma membrane at a preapoptotic stage, and secrete ATP during 
apoptosis. In addition, cells undergoing ICD release the nuclear protein HMGB1 as their 
membranes become permeabilized during secondary necrosis. CRT, ATP, and HMGB1bind to 
CD91, P2RX7, and TLR4, respectively. This facilitates the recruitment of DCs into the tumor 
bed (stimulated by ATP), the engulfment of tumor antigens by DCs (stimulated by CRT), and 
optimal antigen presentation to T cells (stimulated by HMGB1). Altogether, these processes 
result in a potent IL-1β- and IL-17-dependent, IFN-γ-mediated immune response involving 
both γδ T cells and CTLs, which eventually can lead to the eradication of chemotherapy-
resistant tumor cells. (Abbreviations: ATP, adenosine triphosphate; CRT, calreticulin; CTL, 
cytotoxic CD8+ T lymphocyte; DC, dendritic cell; HMGB1, high-mobility group box 1; IFN, 
interferon; IL, interleukin; TLR, Toll-like receptor. Reproduced with permission.[210] Copyright 














switch + Size  
shrinking 
Low pH 1. Detachment of PEG via the 
cleavage of Schiff base bonds at 
weakly acidic tumor extracellular 
pHe. 
2. Cleavage of hydrazone bond 
between Pa and DOX at acidic 





Size shrinking Low pH 1. Aggregated micelle-like 
PDEA blocks were self- 
disassembled into small linear 










Low pH 1. Detachment of PEG via the 
cleavage of benzoic imine bond 
at acidic tumor extracellular pH 
(pHe).  
2. Exposure of hydrophobic 







switch + Size  
shrinking 
Low pH 1. Cleavage of pH sensitive 
DMA groups and exposure of 
positively charged core. 
Doxorubicin 2017[63] 
DMA-PEI-PDHA Surface charge 
switch + Size  
shrinking 
Low pH 1. Cleavage of pH sensitive 
negative charged DMA. 



























































hypoxia Single-electron reduction of 
hydrophobic P-(MIs)n core to 
hydrophilic poly-aminoimidazoles  
by intracellular nitroreductases.  
Doxorubicin 2018[72] 
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intracellular drug 
release 
MMP-2 + pH EGPLGVRGK peptide 
+ pH sensitive 
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4T1 murine breast 
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Table 5. A summary of recent NPs for deep tumor penetration by optimizing surface 
biochemistry.  
Nanoplatform Surface substances for deep penetration Ref 
Porous silicon Sndecylenic acid 2016[219] 
21-arm star block nanoscale 
copolymers 
Zwitterionic poly(carboxybetaine) (PCB) 2016[220] 
DOX-DGL/HN/iRGD iRGD 2018[221] 
iRGD peptide amphiphile-HB 2018[222] 
iNGR-liposome/DOX Tumor-penetrating peptide iNGR (CRNGRGPDC) 2017[223] 
PEG/ Iron-oxide NPs LyP-1 (CGNKRTRGC) 2017[107] 






Table 6. A summary of recent methods for the modulation of ECM via external physical 
energy. 
 
Physical energy Mechanism Ref 
Very low intensity ultrasound Insonation 2019[225] 
NIR light Photothermal ablation 2019[226] 






Table 7. A summary of recent multi-strategies combined NPs for tumoral deep penetration. 
Nanoplatform Functionalized 
component 
Combined strategies Therapeutics Tumor model Ref 




facilitated + drug release 





RGD-αvβ3 integrin + 
MMP-2 cleavage peptide 
+ disulfide bond 
Surface chemistry 
facilitated + Size 
shrinking + intracellular 
drug release 






Acidic cleaved   host–
metal coordination 
bonds +  a 
photosensitizer (ZnPC) 
Size shrinking +  Hypoxic 
normalization (1O2 
generation ) + 
intracellular drug release 














(1O2 generation ) + 
intracellular drug release 




oxides + RGD-αvβ3 
integrin  
Magnetic directing + 
surface chemistry 
facilitated 
Paclitaxel CT26 tumor 2014[229] 
Mag-pH-DS Iron oxide NPs + folate-
PAMAM dendrimers + 
pH responsive 
liposomes 
Magnetic directing + size 
shrinking + surface 
chemistry facilitated 





Hyaluronic acid shells + 
NIR laser sensitive nitric 
oxide donor + 
indocyanine green 
Size shrinking + 
intracellular drug release 
+ modulation of tumor 
microenvironment 
Doxorubicin 4T1 breast 
cancer xenograft 
2018[231] 
DOX-DGL/HN/iRGD iRGD + hyaluronic acid 
shells + indocyanine 
green + nitric oxide 
donors 
Surface chemistry 
facilitated + size shrinking 
+ modulation of tumor 
microenvironment 
(hyperthermia & NO 
release) 








Table 8. A summary of recent deep penetrated NPs with theranostic function. 
Nanoplatform Component for deep penetration Component for imaging Imaging tool Ref 
PLGA NPs RGD-αvβ3 integrin  + 






Hollow mesoporous MnO2 shell 
(break-up under acidic pH) 





Pt + PEG Pt Photoacoustic 
imaging + CT 
2018[231] 




NIR imaging 2016[147] 
IR780 nanodroplets Perfluoropentane (induced 
vascular disruption under 
ultrasound) 










Deep penetration of nanoparticles in the tumor environment is vital in producing 
successful nanomedicines. This review emphasizes the need of smart nanotechnology to 
facilitate the deep penetration of nanomedicines in tumors. 
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